WO2022094602A1 - Proton pump inhibitors for the treatment of diseases characterized by inflammation and/or collagen accumulation - Google Patents
Proton pump inhibitors for the treatment of diseases characterized by inflammation and/or collagen accumulation Download PDFInfo
- Publication number
- WO2022094602A1 WO2022094602A1 PCT/US2021/072126 US2021072126W WO2022094602A1 WO 2022094602 A1 WO2022094602 A1 WO 2022094602A1 US 2021072126 W US2021072126 W US 2021072126W WO 2022094602 A1 WO2022094602 A1 WO 2022094602A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proton pump
- pump inhibitors
- individual
- combinations
- biomarkers
- Prior art date
Links
- 229940126409 proton pump inhibitor Drugs 0.000 title claims abstract description 89
- 102000008186 Collagen Human genes 0.000 title claims abstract description 85
- 108010035532 Collagen Proteins 0.000 title claims abstract description 85
- 229920001436 collagen Polymers 0.000 title claims abstract description 85
- 238000009825 accumulation Methods 0.000 title claims abstract description 69
- 239000000612 proton pump inhibitor Substances 0.000 title claims abstract description 61
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 60
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title abstract description 39
- 201000010099 disease Diseases 0.000 title description 14
- 238000000034 method Methods 0.000 claims abstract description 95
- 230000003902 lesion Effects 0.000 claims abstract description 43
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 38
- 208000035475 disorder Diseases 0.000 claims abstract description 14
- 208000023178 Musculoskeletal disease Diseases 0.000 claims abstract description 10
- 230000001934 delay Effects 0.000 claims abstract description 8
- 239000000090 biomarker Substances 0.000 claims description 71
- 230000000770 proinflammatory effect Effects 0.000 claims description 29
- 229960004770 esomeprazole Drugs 0.000 claims description 28
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 28
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 25
- 230000036470 plasma concentration Effects 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- -1 troche Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 17
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 15
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 208000010412 Glaucoma Diseases 0.000 claims description 11
- 239000000443 aerosol Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- 239000000829 suppository Substances 0.000 claims description 10
- 102000003814 Interleukin-10 Human genes 0.000 claims description 9
- 108090000174 Interleukin-10 Proteins 0.000 claims description 9
- 102000003815 Interleukin-11 Human genes 0.000 claims description 9
- 108090000177 Interleukin-11 Proteins 0.000 claims description 9
- 102000003816 Interleukin-13 Human genes 0.000 claims description 9
- 108090000176 Interleukin-13 Proteins 0.000 claims description 9
- 102000004388 Interleukin-4 Human genes 0.000 claims description 9
- 108090000978 Interleukin-4 Proteins 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 102000016359 Fibronectins Human genes 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 7
- 230000000994 depressogenic effect Effects 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 208000000059 Dyspnea Diseases 0.000 claims description 6
- 206010013975 Dyspnoeas Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 229940124641 pain reliever Drugs 0.000 claims description 6
- 239000006072 paste Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 201000004700 rosacea Diseases 0.000 claims description 6
- 208000013220 shortness of breath Diseases 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 208000026326 Adult-onset Still disease Diseases 0.000 claims description 5
- 208000001839 Antisynthetase syndrome Diseases 0.000 claims description 5
- 206010058029 Arthrofibrosis Diseases 0.000 claims description 5
- 206010006811 Bursitis Diseases 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims description 5
- 206010010984 Corneal abrasion Diseases 0.000 claims description 5
- 206010061788 Corneal infection Diseases 0.000 claims description 5
- 208000028006 Corneal injury Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 208000010201 Exanthema Diseases 0.000 claims description 5
- 208000018137 Extraocular muscle disease Diseases 0.000 claims description 5
- 208000035690 Familial cold urticaria Diseases 0.000 claims description 5
- 206010016228 Fasciitis Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
- 208000004044 Hypesthesia Diseases 0.000 claims description 5
- 208000035894 Immune-mediated necrotising myopathy Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000034693 Laceration Diseases 0.000 claims description 5
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims description 5
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 5
- 208000000112 Myalgia Diseases 0.000 claims description 5
- 208000007256 Nevus Diseases 0.000 claims description 5
- 206010072139 Ocular rosacea Diseases 0.000 claims description 5
- 208000004931 Orbital Myositis Diseases 0.000 claims description 5
- 206010031252 Osteomyelitis Diseases 0.000 claims description 5
- 201000002154 Pterygium Diseases 0.000 claims description 5
- 206010037660 Pyrexia Diseases 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 5
- 208000000491 Tendinopathy Diseases 0.000 claims description 5
- 206010043255 Tendonitis Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 206010047513 Vision blurred Diseases 0.000 claims description 5
- 208000009621 actinic keratosis Diseases 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 208000001120 amyopathic dermatomyositis Diseases 0.000 claims description 5
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 230000004596 appetite loss Effects 0.000 claims description 5
- 239000002948 appetite stimulant Substances 0.000 claims description 5
- 229940029995 appetite stimulants Drugs 0.000 claims description 5
- 239000000607 artificial tear Substances 0.000 claims description 5
- 208000010217 blepharitis Diseases 0.000 claims description 5
- 229940124630 bronchodilator Drugs 0.000 claims description 5
- 239000000168 bronchodilator agent Substances 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 201000002547 conjunctival squamous cell carcinoma Diseases 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229960001334 corticosteroids Drugs 0.000 claims description 5
- 201000001981 dermatomyositis Diseases 0.000 claims description 5
- 201000005884 exanthem Diseases 0.000 claims description 5
- 208000030533 eye disease Diseases 0.000 claims description 5
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims description 5
- 206010016256 fatigue Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 208000034783 hypoesthesia Diseases 0.000 claims description 5
- 208000012101 immune-mediated necrotizing myopathy Diseases 0.000 claims description 5
- 201000008319 inclusion body myositis Diseases 0.000 claims description 5
- 230000004410 intraocular pressure Effects 0.000 claims description 5
- 208000019017 loss of appetite Diseases 0.000 claims description 5
- 235000021266 loss of appetite Nutrition 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 5
- 231100000862 numbness Toxicity 0.000 claims description 5
- 201000010668 orbital plasma cell granuloma Diseases 0.000 claims description 5
- 208000035824 paresthesia Diseases 0.000 claims description 5
- 206010037844 rash Diseases 0.000 claims description 5
- 201000000306 sarcoidosis Diseases 0.000 claims description 5
- 230000037390 scarring Effects 0.000 claims description 5
- 201000009890 sinusitis Diseases 0.000 claims description 5
- 206010040882 skin lesion Diseases 0.000 claims description 5
- 231100000444 skin lesion Toxicity 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 201000004595 synovitis Diseases 0.000 claims description 5
- 201000004415 tendinitis Diseases 0.000 claims description 5
- 230000008719 thickening Effects 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 4
- 206010000591 Acrochordon Diseases 0.000 claims description 4
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 4
- 208000031513 cyst Diseases 0.000 claims description 4
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims description 4
- 229960003568 dexlansoprazole Drugs 0.000 claims description 4
- 239000010408 film Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 229960005019 pantoprazole Drugs 0.000 claims description 4
- 229960004157 rabeprazole Drugs 0.000 claims description 4
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- HRRXCXABAPSOCP-UHFFFAOYSA-N ilaprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC(=CC=C3N=2)N2C=CC=C2)=C1C HRRXCXABAPSOCP-UHFFFAOYSA-N 0.000 claims description 3
- 229950008491 ilaprazole Drugs 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 3
- 102000026633 IL6 Human genes 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 79
- 230000002265 prevention Effects 0.000 abstract description 10
- 230000009467 reduction Effects 0.000 abstract description 7
- 150000002632 lipids Chemical class 0.000 description 25
- 230000037396 body weight Effects 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 206010039710 Scleroderma Diseases 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000009469 supplementation Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108010074051 C-Reactive Protein Proteins 0.000 description 7
- 102100032752 C-reactive protein Human genes 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 229940076144 interleukin-10 Drugs 0.000 description 7
- 229940074383 interleukin-11 Drugs 0.000 description 7
- 229940028885 interleukin-4 Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 244000146510 Pereskia bleo Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000037319 collagen production Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000003380 propellant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000012261 overproduction Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002991 molded plastic Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000036544 posture Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- Embodiments of the disclosure include at least the fields of cell biology, molecular biology, biochemistry, pharmacology, immunology, and medicine.
- Inflammation is involved in a number of pediatric and adult onset disorders. Many of these conditions involve overproduction of a number of pro-inflammatory biomarkers, including C-reactive protein (CRP) and/or pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin 1 beta (ILip), and/or interleukin 6 (IL6), and/or the suppression of a number of anti-inflammatory cytokines, including interleukin 4 (IL4), interleukin 10 (IL10), interleukin 11 (IL11), and/or interleukin 13 (IL13), to drive the inflammatory process. Uncontrolled inflammation could exacerbate the diseases and trigger accumulation of extracellular matrix (ECM) proteins including collagen.
- CCP C-reactive protein
- pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin 1 beta (ILip), and/or interleukin 6 (IL6)
- IL4 interleukin 4
- IL10 interleukin
- TGFP transforming growth factor beta
- Col collagen
- FN fibronectin
- a non-limiting example of these disorders includes osteoarthritis.
- inflammation and/or collagen mediators used in the treatment of the aforementioned clinical disorders.
- many of these agents target single molecules and thus are unable to effectively control the inflammation and/or collagen accumulation.
- Embodiments of the present disclosure are directed to methods and compositions for treating, preventing, delaying onset of, and/or reducing severity of at least one or more musculoskeletal (relating to the bones, muscles, cartilage, ligaments, tendons, joints, and connective tissue) conditions, ocular surface (related to the cornea, conjunctiva, eyelids, or lacrimal glands) conditions, neoplastic lesions, non-neoplastic lesions, or other medical conditions involving uncontrolled inflammation or collagen accumulation.
- musculoskeletal relating to the bones, muscles, cartilage, ligaments, tendons, joints, and connective tissue
- ocular surface related to the cornea, conjunctiva, eyelids, or lacrimal glands
- a neoplastic lesion is an abnormal growth of cells which is generally monoclonal, atypical/dysplastic, autonomous, uncontrolled, and irreversible.
- a non-neoplastic lesion is an abnormal proliferation of otherwise normal cells which is generally polyclonal, normal in structure/function, under control, serves the body’s needs, and reversible.
- the one or more musculoskeletal conditions include at least osteoarthritis; amyopathic dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, juvenile myositis, orbital myositis, and antisynthetase syndrome; cryopyrin associated periodic syndromes including familial cold autoinflammatory syndrome and Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis and synovial fibrosis; arthrofibrosis (including post-partial or post-total joint replacement); tendinitis; fasciitis; systemic inflammatory response syndrome (e.g., after infection, trauma, surgery, etc.); extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’s disease; thyroid orbitopathy; rhinosinusitis; sepsis; diabetic neuropathy;
- the one or more ocular surface conditions include at least dry eye disease, including chemotherapy-induced; uveitis, blepharitis; conjunctivitis; corneal infections; Meibomian gland dysfunction); ocular surface squamous neoplasia; corneal scarring; corneal abrasion, puncture or laceration; pterygium; allergic eye diseases; ocular rosacea; thermal, chemical, cold induced ocular burn; ocular graft vs host disease; cataracts; glaucoma; Fuch’s endothelial dystrophy; age-related macular degeneration, glaucoma; steroid-induced increase in intra-ocular pressure; and diabetic retinopathy.
- dry eye disease including chemotherapy-induced; uveitis, blepharitis; conjunctivitis; corneal infections; Meibomian gland dysfunction); ocular surface squamous neoplasia; corneal scarring; corneal
- One or more neoplastic lesions include at least benign, pre-cancerous, and cancerous tumors.
- One or more neoplastic lesions may occur in all tissue types, including at least bone; connective tissue; endothelium; mesothelium; blood cells; lymphoid cells; muscle; neural tissue; and epithelial tissue.
- One or more neoplastic lesions may present in epithelial tissue, including at least benign skin moles; and skin tags.
- One or more non-neoplastic lesions include at least cysts, nodules, polyps, bumps, and patches.
- One or more non-neoplastic lesions may occur in all tissue types, including at least bone; connective tissue; endothelium; mesothelium; blood cells; lymphoid cells; muscle; neural; epithelial, and neural tissue.
- One or more non-neoplastic lesions may present in epithelial tissue, including actinic keratosis and herpetic lesions.
- Certain embodiments of the disclosure include methods of regulating collagen (such as regulating collagen production, accumulation, processing, distribution, or degradation for example) in an individual.
- collagen is regulated by administering one or more proton pump inhibitors to an individual.
- the proton pump inhibitor may be any proton pump inhibitor provided at any concentration useful for regulating collagen.
- Certain embodiments of the disclosure include methods for treating or preventing scleroderma.
- scleroderma is treated or prevented by administering one or more proton pump inhibitors to an individual.
- the proton pump inhibitor may be any proton pump inhibitor provided at any concentration useful for treating or preventing scleroderma.
- Embodiments of the disclosure include methods and compositions for treatment or prevention of one or more indications where one or more pro-inflammatory biomarkers (as examples only, CRP, TNF-a, IL6, and/or ILip) are involved, such as biomarkers that are elevated with respect to that of the general population.
- Embodiments of the disclosure include methods and compositions for treatment or prevention of one or more indications where one or more antiinflammatory biomarkers (as examples only, IL4, IL10, IL11, and/or IL13) are involved, such as biomarkers that are depressed with respect to that of the general population.
- Embodiments of the disclosure include methods and compositions for treatment or prevention of one or more indications where one or more collagen accumulation biomarkers (as examples only, TGFp, collagen (Col) types 1, 2, 3, 4, 5, laminin, and/or fibronectin) are involved, such as biomarkers that are elevated with respect to that of the general population.
- Methods and compositions of the disclosure concern treatment and/or prevention of uncontrolled inflammation and/or collagen accumulation related to any medical condition.
- the present disclosure is directed to methods of treating, preventing, delaying onset of, or reducing severity of one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation in an individual in need thereof, including the step of administering to the individual an effective amount of one or more proton pump inhibitors, wherein the one or more conditions are treated, prevented, delayed in onset, and/or reduced in severity in the individual.
- the one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation are selected from the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof.
- the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof are selected from the group consisting of osteoarthritis; amyopathic dermatomyositis; inclusion body myositis; immune-mediated necrotizing myopathy; juvenile myositis; orbital myositis; antisynthetase syndrome; cryopyrin associated periodic syndromes; familial cold autoinflammatory syndrome; Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis; synovial fibrosis; arthrofibrosis; post-partial joint replacement; post-total joint replacement; tendinitis; fasciitis; systemic inflammatory response syndrome; extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’
- the administering step treats, prevents, delays onset of, or reduces the severity of uncontrolled inflammation and/or collagen accumulation in the individual.
- the administering step treats, prevents, delays onset of, or reduces the severity of redness, thickening and swelling of the fingers or joints, pale fingers, numbness, tingling, pain, fever, fatigue, rash, loss of appetite, dry eyes, blurry vision, skin lesions, shortness of breath, or combinations thereof.
- the administering step occurs systemically or locally. In specific embodiments, the administering step occurs locally to an area of the musculoskeletal system, the ocular surface, a neoplastic lesion, and/or a non-neoplastic lesion.
- the one or more proton pump inhibitors are formulated alone or in combination with one or more other agents. In specific embodiments, the one or more proton pump inhibitors are administered prior to, during, and/or subsequent to administration of one or more other agents.
- the one or more other agents comprise one or more antifibrotic drugs, one or more appetite stimulants, one or more bronchodilators, one or more artificial tears, one or more corticosteroids, one or more antibiotics, one or more pain relievers, or combinations thereof.
- the one or more proton pump inhibitors are formulated for local administration. In specific embodiments, the one or more proton pump inhibitors are formulated for topical administration. In specific embodiments, the one or more proton pump inhibitors are formulated for intraarticular and/or intratumoral injection. In specific embodiments, the one or more proton pump inhibitors are formulated for administration outside of the alimentary canal. In specific embodiments, the one or more proton pump inhibitors are formulated for administration other than for the stomach.
- the one or more proton pump inhibitors are formulated as a liquid, troche, suppository, cream, solid, tablet, pill, aerosol, gel, film, foam, ointment, paste, cream, syrup, powder, drops, suspension, or combinations thereof.
- the one or more proton pump inhibitors is Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole, Haprazole, or combinations thereof.
- the concentration of the one or more proton pump inhibitors is in a range of l%-100% w/w. In specific embodiments, the concentration of the one or more proton pump inhibitors is not greater than 20% w/w.
- the individual is or is not at risk of a medical condition involving uncontrolled inflammation and/or collagen accumulation, has or has not been tested for a medical condition involving uncontrolled inflammation and/or collagen accumulation, has or has not been diagnosed with a medical condition involving uncontrolled inflammation and/or collagen accumulation, and/or is or is not symptomatic for a medical condition involving uncontrolled inflammation and/or collagen accumulation.
- the individual has or has not been tested for plasma concentrations of pro-inflammatory biomarkers, anti-inflammatory biomarkers, and/or collagen accumulation biomarkers, and/or has or has not been diagnosed with elevated plasma concentrations of pro-inflammatory biomarkers, depressed plasma concentrations of anti- inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers.
- the administering step treats, prevents, delays onset of, or reduces the severity of elevated plasma concentrations of pro-inflammatory biomarkers, depressed plasma concentrations of anti-inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers in the individual.
- said pro- inflammatory biomarkers are CRP, TNF-a, IL6, ILip, or combinations thereof
- said antiinflammatory biomarkers are IL4, IL10, IL11, IL13, or combinations thereof
- said collagen accumulation biomarkers are TGFp, Col 1, Col 2, Col 3, Col 4, Col 5, laminin, fibronectin, or combinations thereof.
- the individual has or is at risk for a medical condition involving uncontrolled inflammation and/or collagen accumulation selected from the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non- neoplastic lesions, or combinations thereof.
- the individual has or is at risk for osteoarthritis; amyopathic dermatomyositis; inclusion body myositis; immune-mediated necrotizing myopathy; juvenile myositis; orbital myositis; antisynthetase syndrome; cryopyrin associated periodic syndromes; familial cold autoinflammatory syndrome; Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis; synovial fibrosis; arthro fibrosis; post-partial joint replacement; post-total joint replacement; tendinitis; fasciitis; systemic inflammatory response syndrome; extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’s disease; thyroid orbitopathy; rhinosinusitis; sepsis; diabetic neuropathy; chronic obstructive pulmonary disease; liver fibros
- the individual has redness, thickening and swelling of the fingers or joints, pale fingers, numbness, tingling, pain, fever, fatigue, rash, loss of appetite, dry eyes, blurry vision, skin lesions, shortness of breath, or combinations thereof.
- the individual has or is at risk for a medical condition involving uncontrolled inflammation and/or collagen accumulation selected from the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non- neoplastic lesions, or combinations thereof, and wherein the one or more proton pump inhibitors is Esomeprazole that is topically formulated.
- FIGS. 1A-1B show the effect of esomeprazole on the regulation of collagen.
- Patient derived fibroblasts from scleroderma patients with limited (FIG. 1A) or diffuse (FIG. IB) were untreated (control), stimulated with only TGFB (TGF-B), or stimulated and treated with various concentrations of esomeprazole (TGF-B + Eso).
- FIGS. 2A-2B show the effect of esomeprazole on body weight in mice with scleroderma.
- Scleroderma mouse models were untreated (Bleo control) or administered esomeprazole (Bleo + Eso) either topically (FIG. 2A) or systemically (FIG. 2B).
- FIGS. 3A-3B show the effect of esomeprazole on organ weigh in mice with scleroderma. Untreated control mice (No bleo) or a mouse model of scleroderma were untreated (Bleo Control) or treated with esomeprazole (Bleo + Eso) either topically (FIG. 3A) or systemically (FIG. 3B).
- a” or “an” may mean one or more.
- the words “a” or “an” when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one.
- “another” may mean at least a second or more.
- the terms “having”, “including”, “containing” and “comprising” are interchangeable and one of skill in the art is cognizant that these terms are open ended terms.
- Some embodiments of the disclosure may consist of or consist essentially of one or more elements, method steps, and/or methods of the disclosure. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.
- administered refers to any method of providing a composition to an individual such that the composition has its intended effect on the individual.
- one method of administering is by a direct mechanism such as, local tissue administration, transdermal patch, topical, etc.
- pharmaceutically refers to molecular entities and compositions that do not produce unacceptable adverse, allergic, or other untoward reactions when administered to an animal or a human.
- pharmaceutically acceptable carrier includes any and all solvents, or a dispersion medium including, but not limited to, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils, coatings, isotonic and absorption delaying agents, liposome, commercially available cleansers, and the like. Supplementary bioactive ingredients also can be incorporated into such carriers.
- Pharmaceutically acceptable carriers may comprise surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.
- preventing refers to the methods that avert a medical condition from occurring in an individual, including averting the onset of at least one symptom of the medical condition.
- subject refers to a human or animal that may or may not be housed in a medical facility and may be treated as an outpatient of a medical facility.
- the individual may be receiving one or more medical compositions via the internet.
- An individual may comprise any age of a human or non-human animal and therefore includes both adult and juveniles (z.e., children) and infants. It is not intended that the term "individual” connote a need for medical treatment, therefore, an individual may voluntarily or involuntarily be part of experimentation whether clinical or in support of basic science studies.
- subject refers to any organism or animal subject that is an object of a method or material, including mammals, e.g., humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodents), horses, and transgenic non-human animals.
- mammals e.g., humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodents), horses, and transgenic non-human animals.
- mammals e.g., humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodent
- an effective amount is synonymous with “effective amount”, “therapeutically effective dose”, and/or “effective dose” and refers to the amount of compound that will elicit the biological, cosmetic or clinical response being sought by the practitioner in an individual in need thereof.
- an effective amount is the amount sufficient to inhibit elevated pro-inflammatory or collagen accumulation biomarkers in an individual.
- an effective amount is the amount sufficient to reduce elevated pro-inflammatory or collagen production biomarkers in an individual.
- an effective amount is an amount sufficient to prevent uncontrolled inflammation and/or collagen accumulation in an individual.
- an effective amount is an amount sufficient to reduce elevated inflammation and/or collagen accumulation in an individual.
- an effective amount is an amount sufficient to prevent the symptoms of elevated inflammation and/or collagen accumulation in an individual.
- an effective amount is an amount sufficient to ameliorate the symptoms of elevated inflammation and/or collagen accumulation in an individual.
- the appropriate effective amount to be administered for a particular application of the disclosed methods can be determined by those skilled in the art, using the guidance provided herein. For example, an effective amount can be extrapolated from in vitro and in vivo assays as described in the present specification. One skilled in the art will recognize that the condition of the individual can be monitored throughout the course of therapy and that the effective amount of a compound or composition disclosed herein that is administered can be adjusted accordingly.
- Treatment means a method of reducing the effects of a disease or condition.
- Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms.
- the treatment can be any reduction from pre-treatment levels and can be but is not limited to the complete ablation of the disease, condition, or the symptoms of the disease or condition. Therefore, in the disclosed methods, treatment” can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or the disease progression, including reduction in the severity of at least one symptom of the disease.
- a disclosed method for reducing inflammation in a subject is considered to be a treatment if there is a detectable reduction in the level of pro-inflammatory biomarkers in a subject when compared to pre-treatment levels in the same subject or control subjects.
- the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
- treatment does not necessarily refer to a cure of the disease or condition, but an improvement in the outlook of a disease or condition.
- treatment refers to the lessening in severity or extent of at least one symptom and may alternatively or in addition refer to a delay in the onset of at least one symptom. II. Examples of Methods of Use
- PPIs Proton pump inhibitors
- IV intravenous
- Embodiments of the disclosure concern the use of one or more proton pump inhibitors (PPIs) that are effective for a medical condition other than gastritis or gastritis-related purposes.
- the methods are for medical conditions directly or indirectly affected by uncontrolled inflammation and/or accumulated collagen, including but not limited to musculoskeletal conditions, ocular surface conditions, or non-neoplastic lesions.
- the methods encompass medical conditions in which the ocular system or the skin, epidermis, dermis, and/or mucus membranes are affected because of exposure to one or more external conditions and/or in which the musculoskeletal system, the ocular surface, or the skin, epidermis, dermis, and/or mucus membranes are affected because of internal causes, such as a genetic or other cause including underlying conditions such as diabetes.
- the methods may be utilized prior to exposure to the external condition, during exposure to the external condition, and/or after exposure to the external condition.
- the methods may be utilized prior to onset of a symptom of the condition and/or after onset of a symptom of the condition.
- the individual may prophylactically be subject to methods of the disclosure.
- the methods include treatment or prevention for any inflammation-related and/or fibrosis-related medical condition.
- the methods provide therapy or prophylaxis to the musculoskeletal system, the ocular surface, skin, dermis, epidermis, and/or mucus membranes.
- the external cause of the medical condition is environmental, such as exposure to chemical(s), radiation of any kind, and/or one or more allergens or pathogens.
- the internal cause of the medical condition is an infection, a trauma, an allergic reaction, an injury, and/or a genetic condition.
- an individual is at risk of having a medical condition, such as a musculoskeletal disorder, ocular surface disorder, neoplastic lesion, non-neoplastic lesion, or combinations thereof.
- a medical condition such as a musculoskeletal disorder, ocular surface disorder, neoplastic lesion, non-neoplastic lesion, or combinations thereof.
- An individual may be at risk of a musculoskeletal disorder from poor posture, repetitive movements, forceful movements (including heavy lifting or excessive pressure), vibrations, overexertion, work-related activities, awkward postures, stress, obesity, smoking, aging, or a combination thereof.
- An individual may be at risk of an ocular surface disorder from having diabetes, having glaucoma, being over- medicated, advancing age, gender, a dry environment, smoking, smoke exposure, having connective tissue disorder, a vitamin A deficiency, a prior eye surgery, having rosacea, or a combination thereof.
- An individual may be at risk of a neoplastic lesion from advancing age, a personal or family history of cancer, using tobacco, obesity, using alcohol, certain viral infections (such as human papillomavirus), exposure to carcinogens, exposure to radiation, or a combination thereof.
- An individual may be at risk of a non-neoplastic lesion from congenital issues, degenerative issues, inflammation, adaptive changes, reparative changes, or a combination thereof.
- the individual administered the compositions disclosed herein, including any PPI disclosed herein has, or is suspected of having, one or more treatment related injuries.
- the individual is administered any of the compositions disclosed herein to prevent or reduce a treatment related injury.
- the injury may be from any treatment, such as a cancer treatment.
- the treatment may comprise a tyrosine kinase inhibitor (TKI).
- the injury may comprise any lung injury, such as a treatment- induced lung injury.
- the individual has, or is suspected of having, interstitial lung disease, pneumonitis, and/or TKI-induced lung disease.
- the individual is administered any composition disclosed herein to prevent or reduce interstitial lung disease, pneumonitis, and/or TKI-induced lung disease.
- the individual has, or is suspected of having, an inflammatory condition.
- the individual is administered any composition disclosed herein to prevent or reduce an inflammatory condition.
- an individual is tested for a medical condition in order to determine whether the individual should be treated, including treated with any methods or compositions disclosed herein.
- the medical condition may involve uncontrolled inflammation, such as any autoimmune disease, cancer, heart disease, or degenerative disease.
- the medical condition may involve collagen accumulation.
- the individual may be tested for inflammation.
- the individual is tested for one or more biomarkers of inflammation, such as C-reactive protein.
- the C-reactive protein in an individual to be treated may be more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 mg/L or more.
- ESR erythrocyte sedimentation rate
- PV plasma viscosity
- the ESR in an individual to be treated may be more than 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, mm/hr or more.
- the PV in an individual to be treated may be outside a normal range, including outside 1.10-1.30 mPa or outside of 1.50-1.72 mPa.
- collagen accumulation is tested by immunohistochemistry, such as by trichrome staining or using molecules reactive or capable of binding to any collagen molecule.
- the individual may be tested for plasma concentrations of pro-inflammatory biomarkers, anti-inflammatory biomarkers, and/or collagen accumulation biomarkers.
- an additional treatment or preventative therapy may be provided in combination with the disclosed treatment.
- the additional treatment or preventative therapy is for pain, allergy, infection, inflammation, shortness of breath, and/or bleeding.
- the disclosed treatment may precede, follow, or both, an additional treatment or preventative therapy by intervals ranging from minutes to weeks to months.
- an additional treatment or preventative therapy by intervals ranging from minutes to weeks to months.
- the disclosed treatment and the additional agent are provided separately to an individual, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the disclosed treatment and the additional agent would still be able to exert an advantageously combined effect against the medical condition.
- PPIs are normally utilized for gastric conditions, but this disclosure encompasses reformulation of their use for conditions other than gastric conditions to formulations useful for one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation. This characteristic of PPIs is devoid of the indication (z.e., treatment of gastritis) for which they are FDA- approved. PPIs directly regulate many of the pro -inflammatory and/or collagen accumulation biomarkers generated in response to many medical conditions, as encompassed herein. Many of these PPI-regulated cytokines are reported to be upregulated in musculoskeletal conditions, ocular surface conditions, and/or non-neoplastic lesions, for example.
- Embodiments of the disclosure include one or more PPIs for treatment of one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation.
- the PPIs may be formulated into any kind of composition suitable for the treatment or prevention required.
- the PPIs may be formulated for local or systemic administration, although in particular embodiments the administration is not for a gastric application. When more than one PPI is provided to an individual, they may or may not be formulated in the same composition.
- the present disclosure demonstrates the direct application of topical PPI (esomeprazole) cream to the skin to prevent and/or treat collagen accumulation and confirms control of collagen secretion and wound healing in vitro and in an animal model of scleroderma.
- PPI esomeprazole
- the PPIs can be reformulated in various preparations including cream, liquid, troche, and suppository to prevent and/or treat collagen accumulation and to promote wound healing, as examples.
- the PPI is Esomeprazole, Omeprazole, Lansoprazole, Dexlansoprazole, Pantoprazole, Rabeprazole, Ilaprazole, or a combination thereof.
- PPIs Esomeprazole, Omeprazole, Lansoprazole, Dexlansoprazole, Pantoprazole, Rabeprazole, Ilaprazole, or a combination thereof.
- PPIs Esomeprazole, Omeprazole, Lansoprazole, Dexlansoprazole, Pantoprazole, Rabeprazole, Ilaprazole, or a combination thereof.
- the one or more PPIs are formulated in a composition with one or more other agents for a therapeutic or other purpose.
- examples include one or more antifibrotic drugs, appetite stimulants, bronchodilators, artificial tears, one or more corticosteroids, one or more antibiotics, one or more pain relievers, or a combination thereof.
- One particular embodiment of a composition comprises one or more PPIs with lidocaine that for example may be used to simultaneously relieve pain and treat the inflammatory and/or fibrotic condition(s).
- compositions of the present disclosure comprise an effective amount of one or more PPIs dissolved or dispersed in a pharmaceutically acceptable carrier.
- a pharmaceutical composition that contains at least one PPI or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington: The Science and Practice of Pharmacy, 21 st Ed. Lippincott Williams and Wilkins, 2005, incorporated herein by reference.
- preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.
- the one or more PPIs may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection.
- the one or more PPIs can be administered topically, locally, intradermally, transdermally, subcutaneously, mucosally, in creams or gels, and so forth, although in certain cases the PPIs are administered intravenously, intrathecally, intraarterially, intratumorally, intraarticularly, intraperitoneally, sublingually, intranasally, intravaginally, intrarectally, intramuscularly, orally, by inhalation (e.g., aerosol inhalation), injection (intraarticular, subcutaneous, intratumoral, etc.), as eye drops, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would
- the one or more PPIs may be formulated into a composition in a free base, neutral or salt form.
- Pharmaceutically acceptable salts include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, magnesium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine.
- solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
- the formulations are easily administered in a variety of dosage forms such as formulated for parenteral administrations such as injectable solutions, or aerosols for delivery to the lungs, or formulated for alimentary administrations such as drug release capsules and the like.
- the composition of the present disclosure suitable for administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent.
- the carrier should be assimilable and includes liquid, semi-solid, pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of the composition contained therein, its use in administrable composition for use in practicing the methods of the present disclosure is appropriate.
- carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof.
- composition may also comprise various antioxidants, including but not limited to sodium metabisulfite, glutathione or N-acetyl cysteine, to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
- parabens e.g., methylparabens, propylparabens
- chlorobutanol phenol
- sorbic acid thimerosal or combinations thereof.
- composition may be combined with the carrier in any convenient and practical manner, i.e., by solution, suspension, emulsification, admixture, encapsulation, absorption and the like. Such procedures are routine for those skilled in the art.
- the composition is combined or mixed thoroughly with a semi-solid or solid carrier.
- the mixing can be carried out in any convenient manner such as grinding.
- Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, e.g., denaturation in the stomach.
- stabilizers for use in the composition include buffers, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.
- the present disclosure may encompass the use of a pharmaceutical lipid vehicle compositions that include one or more PPIs, one or more lipids, and an aqueous solvent.
- lipid will be defined to include any of a broad range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds are well known to those of skill in the art, and as the term “lipid” is used herein, it is not limited to any particular structure. Examples include compounds which contain long-chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally occurring or synthetic (/'. ⁇ ?. , designed or produced by man). However, a lipid is usually a biological substance.
- Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof.
- neutral fats phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof.
- lipids are also encompassed by the compositions and methods of the present disclosure.
- the PPI(s) may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art.
- the dispersion may or may not result in the formation of liposomes.
- the actual dosage amount of a composition of the present disclosure administered to an individual can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, and/or on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the individual. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual.
- compositions may comprise, for example, at least about 0.1% of an active compound.
- the active compound may comprise between about 1% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
- the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound.
- Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
- a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 milligram /kg/body weight or more per administration, and any range derivable therein.
- a range of about 5 milligram /kg/body weight to about 100 milligram /kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc. can be administered, based on the numbers described above.
- the PPI is formulated in a particular concentration in a composition.
- the PPI is formulated in a range of l%-100% w/w, or any range derivable therein.
- the PPI is formulated in a range of l%-100%, 1 %-75%, l%-50%, l%-25%, 10%-100%, 10%-75%, 10%-50%, 25%-100%, 25%-75%, 25%-50%, 1%- 20%, 1%-18%, 1%-16%, 1%-15%, 1%-12%, l%-10%, l%-8%, l%-6%, l%-5%, l%-4%, 1%- 3%, l%-2%, 2%-5%, 2%-4%, 2%-3%, 3%-5%, 3%-4%, 4%-5%, 5%-20%, 5%-15%, 5%-10%, 10%-20%, 10%- 15%, 12%-15%, 12%-20% w/
- the PPI may be formulated in a concentration of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% w/w, in some cases.
- the concentration of proton pump inhibitor is not greater than 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 20%, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% w/w.
- one or more PPIs may be administered via a parenteral route.
- parenteral includes routes that bypass the alimentary tract.
- the pharmaceutical compositions disclosed herein may be administered for example, but not limited to intravenously, intradermally, intramuscularly, intraarterially, intratumorally, intraarticularly, intrathecally, subcutaneous, or intraperitoneally such as described in U.S. Pat. Nos. 6,7537,514, 6,613,308, 5,466,468, 5,543,158; 5,641,515; and 5,399,363 (each specifically incorporated herein by reference in its entirety).
- Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Patent 5,466,468, specifically incorporated herein by reference in its entirety).
- the form must be sterile and must be fluid to the extent that easy injectability exists. In certain embodiments, it must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (z.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- aqueous solutions for parenteral administration in an aqueous solution
- the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration.
- sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage may be dissolved in isotonic NaCl solution and either added hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580).
- Sterile injectable solutions may be prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the methods of preparation include vacuum-drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- a powdered composition may be combined with a liquid carrier such as, e.g., water or a saline solution, with or without a stabilizing agent.
- the one or more PPIs may be formulated to be administered via an alimentary route.
- Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract.
- the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually.
- these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft- shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz etal., 1997; Hwang etal., 1998; U.S. Pat. Nos. 5,641,515; 5,580,579 and 5,792, 451, each specifically incorporated herein by reference in its entirety).
- the tablets, troches, pills, capsules and the like may also contain the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, corn starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc.
- a binder such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof
- an excipient such as, for
- the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. When the dosage form is a capsule, it may contain, in addition to materials of the above type, carriers such as a liquid carrier. Gelatin capsules, tablets, or pills may be enterically coated. Enteric coatings prevent denaturation of the composition in the stomach or upper bowel where the pH is acidic. See, e.g., U.S. Pat. No. 5,629,001.
- a syrup of elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.
- compositions of the present disclosure may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, mucoadhesive agent, oral spray, or sublingual orally-administered formulation.
- a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution).
- the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically- effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.
- a composition may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.
- the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.
- Additional formulations that are suitable for other modes of alimentary administration include suppositories. Suppositories are solid dosage forms of various weights and shapes, usually medicated, for insertion into the rectum.
- suppositories soften, melt or dissolve in the cavity fluids.
- traditional carriers may include, for example, polyalkylene glycols, triglycerides or combinations thereof.
- suppositories may be formed from mixtures containing, for example, the active ingredient in the range of about 0.5% to about 10%, and preferably about 1% to about 2%.
- the active compound PPI(s) may be formulated for administration via various miscellaneous routes, for example, topical (/'. ⁇ ?., transdermal with or without the aid of patches or bandages) administration, mucosal administration (intranasal, oral, vaginal, etc.) and/or inhalation.
- compositions for topical administration may include the active compound formulated for a medicated application such as an ointment, paste, cream, gel, or powder.
- Ointments include all oleaginous, adsorption, emulsion and water-solubility based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only.
- Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones and luarocapram.
- compositions for topical application include polyethylene glycol, lanolin, cold cream and petrolatum as well as any other suitable absorption, emulsion or water-soluble ointment base.
- Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the active ingredient and provide for a homogenous mixture.
- Transdermal administration of the present disclosure may also comprise the use of a "patch".
- the patch may supply one or more active substances at a predetermined rate and in a continuous manner over a fixed period of time.
- the pharmaceutical compositions may be delivered by eye drops, eye suspensions, eye gels, eye ointments, intranasal sprays, inhalation, and/or other aerosol delivery vehicles.
- Methods for delivering compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in its entirety).
- the delivery of drugs using intranasal microparticle resins Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No.
- aerosol refers to a colloidal system of finely divided solid of liquid particles dispersed in a liquefied or pressurized gas propellant.
- the typical aerosol of the present disclosure for inhalation will consist of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent.
- Suitable propellants include hydrocarbons and hydrocarbon ethers.
- Suitable containers will vary according to the pressure requirements of the propellant.
- Administration of the aerosol will vary according to subject’s age, weight and the severity and response of the symptoms.
- kits will thus comprise, in suitable container means, a PPI(s) and a lipid, and/or an additional agent of the present disclosure.
- the one or more PPI compositions may be formulated as a liquid, troche, suppository, cream, solid, tablet, pill, aerosol, gel, film, foam, ointment, paste, cream, syrup, powder, or combination thereof, for example.
- a first PPI is packaged with a first other therapeutic while a second packaging comprises a second PPI packaged with a second other therapeutic.
- a PPI and a pain reliever(s) and optionally another therapeutic are packaged in the same package they may be housed within different containers within the package.
- kits may comprise a suitably aliquoted PPIs, lipid and/or additional agent compositions of the present disclosure.
- the components of the kits may be packaged either in aqueous media or in lyophilized form.
- the container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in the kit, the kit also will generally contain a second, third or other additional container or compartment into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial.
- kits of the present disclosure also will typically include a means for containing the one or more PPIs, lipid, additional agent, and any other reagent containers in close confinement for commercial sale.
- Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.
- the components of the kit may be provided as dried powder(s).
- the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.
- the container means will generally include at least one vial, test tube, flask, bottle, syringe and/or other container means or compartment in which the formulation(s) are placed, preferably, suitably allocated.
- the kits may also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.
- kits of the present disclosure will also typically include a means for containing the vials in close confinement for commercial sale, such as, e.g., injection and/or blow-molded plastic containers into which the desired vials are retained.
- a means for containing the vials in close confinement for commercial sale such as, e.g., injection and/or blow-molded plastic containers into which the desired vials are retained.
- levels of pro-inflammatory biomarkers are being studied in subjects diagnosed with inflammation condition before and after proton pump inhibitor supplementation or placebo, for 14-21 days.
- a group of subjects without inflammation is serving as a control.
- Levels of pro-inflammatory biomarkers are being measured in all subjects as levels of CRP, TNFa, IL6, and/or ILip in blood. Results are showing that levels of pro-inflammatory biomarkers are improving only in patients with inflammation who receive proton pump inhibitor supplementation, and not in patients with inflammation who receive placebo. Further analyses are showing that the levels of pro-inflammatory biomarkers in subjects with inflammation are decreasing to approximate values in subjects without inflammation.
- levels of collagen accumulation biomarkers are being studied in subjects diagnosed with collagen accumulation before and after proton pump inhibitor supplementation or placebo, for 14-21 days.
- a group of subjects without collagen accumulation is serving as a control.
- Levels of collagen accumulation biomarkers are being measured in all subjects as levels of TGFp, Collagen (Col) types 1, 2, 3, 4, 5, fibronectin, and/or laminin in blood. Results are showing that levels of collagen accumulation biomarkers are decreasing only in patients with collagen accumulation who receive proton pump inhibitor supplementation, and not in patients with collagen accumulation who receive placebo. Further analyses are showing that the levels of collagen accumulation biomarkers in subjects with fibrosis are decreasing to approximate values in subjects without fibrosis.
- levels of anti-inflammatory biomarkers are being studied in subjects diagnosed with inflammation before and after proton pump inhibitor supplementation or placebo, for 14-21 days.
- a group of subjects without inflammation is serving as a control.
- Levels of anti-inflammatory biomarkers are being measured in all subjects as levels of IL4, IL10, IL11, and IL13 in blood. Results are showing that levels of anti-inflammatory biomarkers are increasing only in patients with inflammation who receive proton pump inhibitor supplementation, and not in patients with inflammation who receive placebo. Further analyses are showing that the levels of anti-inflammatory biomarkers in subjects with inflammation are increasing to approximate values in subjects without inflammation.
- FIGS. 1A and IB provide an example of a particular embodiment of the disclosure wherein the PPI esomeprazole favorably regulates collagen production in scleroderma patient- derived skin fibroblasts from limited (FIG. 1A) and diffuse (FIG. IB) disease compared to TGFP- stimulated cells that are not treated with the drug.
- FIGS. 2A-2B provide an example of a particular embodiment of the disclosure wherein the PPI esomeprazole, applied topically at 2% (FIG. 2A) or systemically at 60 mg/kg (FIG. 2B), improves the overall health in a mouse model of scleroderma as shown by the return of body weight to baseline levels compared to control animals not treated with esomeprazole.
- FIGS. 3A-3B provide an example of a particular embodiment of the disclosure wherein the PPI esomeprazole, applied topically at 2% (FIG. 3A) or systemically at 60 mg/kg (FIG. 3B), does not adversely affect organ weight in a mouse model of scleroderma as shown by the lack of difference in the weight of the lungs, heart, and kidneys compared to control animals not treated with esomeprazole.
- examples of molecular, cell biological, and animal testing show that PPIs regulate processes involved in tissue inflammation and/or collagen overproduction.
- the present disclosure confirmed that the PPI esomeprazole inhibited pro- inflammatory cytokines in primary human endothelial cells and simultaneously controls several pro-inflammatory molecules including TNFa, ILip, and IL6.
- the present disclosure further confirmed that PPIs controlled the proliferation of primary human fibroblasts (cells that are primarily responsible for collagen production) and the deposition of collagen.
- the present disclosure confirmed that PPIs controlled a network of extracellular matrix proteins including several collagen types, and induced wound healing related proteins.
- the present disclosure confirmed that PPIs controlled the degree of collagen deposition and accelerated wound healing.
- the PPI esomeprazole in an in vitro assay, is decreasing collagen accumulation biomarkers in primary human endothelial cells and simultaneously decreasing concentrations of several collagen accumulation molecules including TGFp, Collagen 1, 2, 3, 4, 5. In certain aspects, in an in vitro assay, the PPI esomeprazole is increasing anti-inflammatory cytokines in primary human endothelial cells and simultaneously increasing concentrations of several anti-inflammatory molecules including IL4, IL10, IL11, and/or IL13.
- proton pump inhibitor supplementation in a randomized clinical trial, is reducing levels of pro-inflammatory biomarkers versus a placebo in subjects diagnosed with inflammation. In certain aspects, in a randomized clinical trial, proton pump inhibitor supplementation is reducing levels of collagen accumulation biomarkers versus a placebo in subjects diagnosed with collagen accumulation. In certain aspects, in a randomized clinical trial, proton pump inhibitor supplementation is increasing levels of anti-inflammatory biomarkers versus a placebo in subjects diagnosed with inflammation.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Embodiments of the disclosure include methods and compositions related to treatment, prevention, delay of onset, or reduction in severity of medical conditions involved in uncontrolled inflammation and/or collagen accumulation. Uncontrolled inflammation or collagen accumulation including, but not limited to, musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof. In particular embodiments, one or more proton pump inhibitors are provided to an individual in need thereof. In some embodiments one or more proton pump inhibitors are provided to an individual having one or more musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof. In some embodiments, the providing step treats, prevents, delays onset, or reduces the severity of one or more musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof.
Description
PROTON PUMP INHIBITORS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION AND/OR COLLAGEN ACCUMULATION
[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 63/107,948, filed October 30, 2020, which is incorporated by reference herein in its entirety.
TECHNICAL FIELD
[0002] Embodiments of the disclosure include at least the fields of cell biology, molecular biology, biochemistry, pharmacology, immunology, and medicine.
BACKGROUND
[0003] Inflammation is involved in a number of pediatric and adult onset disorders. Many of these conditions involve overproduction of a number of pro-inflammatory biomarkers, including C-reactive protein (CRP) and/or pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin 1 beta (ILip), and/or interleukin 6 (IL6), and/or the suppression of a number of anti-inflammatory cytokines, including interleukin 4 (IL4), interleukin 10 (IL10), interleukin 11 (IL11), and/or interleukin 13 (IL13), to drive the inflammatory process. Uncontrolled inflammation could exacerbate the diseases and trigger accumulation of extracellular matrix (ECM) proteins including collagen. There are a number of human disorders that are characterized by accumulation of abnormal levels of collagen and overproduction of a number of collagen accumulation biomarkers, including transforming growth factor beta (TGFP), collagen (Col) types 1, 2, 3, 4, 5, laminin, and/or fibronectin (FN). A non-limiting example of these disorders includes osteoarthritis. There are a number of inflammation and/or collagen mediators used in the treatment of the aforementioned clinical disorders. However, many of these agents target single molecules and thus are unable to effectively control the inflammation and/or collagen accumulation. As a result, there are millions of patients with one or more of the aforementioned conditions who are not effectively treated by these therapeutic interventions.
BRIEF SUMMARY
[0004] The present disclosure satisfies a long-felt need in the art of providing effective therapies for medical conditions involving uncontrolled inflammation or collagen accumulation, among other medical conditions. Embodiments of the present disclosure are directed to methods and compositions for treating, preventing, delaying onset of, and/or reducing severity of at least
one or more musculoskeletal (relating to the bones, muscles, cartilage, ligaments, tendons, joints, and connective tissue) conditions, ocular surface (related to the cornea, conjunctiva, eyelids, or lacrimal glands) conditions, neoplastic lesions, non-neoplastic lesions, or other medical conditions involving uncontrolled inflammation or collagen accumulation. A neoplastic lesion is an abnormal growth of cells which is generally monoclonal, atypical/dysplastic, autonomous, uncontrolled, and irreversible. A non-neoplastic lesion is an abnormal proliferation of otherwise normal cells which is generally polyclonal, normal in structure/function, under control, serves the body’s needs, and reversible.
[0005] The one or more musculoskeletal conditions include at least osteoarthritis; amyopathic dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, juvenile myositis, orbital myositis, and antisynthetase syndrome; cryopyrin associated periodic syndromes including familial cold autoinflammatory syndrome and Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis and synovial fibrosis; arthrofibrosis (including post-partial or post-total joint replacement); tendinitis; fasciitis; systemic inflammatory response syndrome (e.g., after infection, trauma, surgery, etc.); extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’s disease; thyroid orbitopathy; rhinosinusitis; sepsis; diabetic neuropathy; chronic obstructive pulmonary disease; and liver fibrosis.
[0006] The one or more ocular surface conditions include at least dry eye disease, including chemotherapy-induced; uveitis, blepharitis; conjunctivitis; corneal infections; Meibomian gland dysfunction); ocular surface squamous neoplasia; corneal scarring; corneal abrasion, puncture or laceration; pterygium; allergic eye diseases; ocular rosacea; thermal, chemical, cold induced ocular burn; ocular graft vs host disease; cataracts; glaucoma; Fuch’s endothelial dystrophy; age-related macular degeneration, glaucoma; steroid-induced increase in intra-ocular pressure; and diabetic retinopathy.
[0007] One or more neoplastic lesions include at least benign, pre-cancerous, and cancerous tumors. One or more neoplastic lesions may occur in all tissue types, including at least bone; connective tissue; endothelium; mesothelium; blood cells; lymphoid cells; muscle; neural tissue; and epithelial tissue. One or more neoplastic lesions may present in epithelial tissue, including at least benign skin moles; and skin tags. One or more non-neoplastic lesions include at least cysts, nodules, polyps, bumps, and patches. One or more non-neoplastic lesions may occur
in all tissue types, including at least bone; connective tissue; endothelium; mesothelium; blood cells; lymphoid cells; muscle; neural; epithelial, and neural tissue. One or more non-neoplastic lesions may present in epithelial tissue, including actinic keratosis and herpetic lesions.
[0008] Certain embodiments of the disclosure include methods of regulating collagen (such as regulating collagen production, accumulation, processing, distribution, or degradation for example) in an individual. In some embodiments, collagen is regulated by administering one or more proton pump inhibitors to an individual. The proton pump inhibitor may be any proton pump inhibitor provided at any concentration useful for regulating collagen.
[0009] Certain embodiments of the disclosure include methods for treating or preventing scleroderma. In some embodiments, scleroderma is treated or prevented by administering one or more proton pump inhibitors to an individual. The proton pump inhibitor may be any proton pump inhibitor provided at any concentration useful for treating or preventing scleroderma.
[0010] Embodiments of the disclosure include methods and compositions for treatment or prevention of one or more indications where one or more pro-inflammatory biomarkers (as examples only, CRP, TNF-a, IL6, and/or ILip) are involved, such as biomarkers that are elevated with respect to that of the general population. Embodiments of the disclosure include methods and compositions for treatment or prevention of one or more indications where one or more antiinflammatory biomarkers (as examples only, IL4, IL10, IL11, and/or IL13) are involved, such as biomarkers that are depressed with respect to that of the general population. Embodiments of the disclosure include methods and compositions for treatment or prevention of one or more indications where one or more collagen accumulation biomarkers (as examples only, TGFp, collagen (Col) types 1, 2, 3, 4, 5, laminin, and/or fibronectin) are involved, such as biomarkers that are elevated with respect to that of the general population. Methods and compositions of the disclosure concern treatment and/or prevention of uncontrolled inflammation and/or collagen accumulation related to any medical condition.
[0011] The present disclosure is directed to methods of treating, preventing, delaying onset of, or reducing severity of one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation in an individual in need thereof, including the step of administering to the individual an effective amount of one or more proton pump inhibitors, wherein the one or more conditions are treated, prevented, delayed in onset, and/or reduced in severity in the individual.
[0012] In specific embodiments, the one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation are selected from the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof.
[0013] In specific embodiments, the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof, are selected from the group consisting of osteoarthritis; amyopathic dermatomyositis; inclusion body myositis; immune-mediated necrotizing myopathy; juvenile myositis; orbital myositis; antisynthetase syndrome; cryopyrin associated periodic syndromes; familial cold autoinflammatory syndrome; Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis; synovial fibrosis; arthrofibrosis; post-partial joint replacement; post-total joint replacement; tendinitis; fasciitis; systemic inflammatory response syndrome; extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’s disease; thyroid orbitopathy; rhinosinusitis; sepsis; diabetic neuropathy; chronic obstructive pulmonary disease; liver fibrosis; dry eye disease; chemotherapy-induced dry eye disease; uveitis, blepharitis; conjunctivitis; corneal infections; Meibomian gland dysfunction; ocular surface squamous neoplasia; corneal scarring; corneal abrasion, puncture or laceration;; pterygium; allergic eye diseases; ocular rosacea; ocular bum; ocular graft vs host disease; cataracts; glaucoma; Fuch’s endothelial dystrophy; age-related macular degeneration, glaucoma; steroid-induced increase in intra-ocular pressure; diabetic retinopathy; benign, pre-cancerous, or cancerous tumors; benign skin moles; skin tags cysts; nodules; polyps; bumps; patches; actinic keratosis; herpetic lesions; or combinations thereof.
[0014] In specific embodiments, the administering step treats, prevents, delays onset of, or reduces the severity of uncontrolled inflammation and/or collagen accumulation in the individual. In specific embodiments, the administering step treats, prevents, delays onset of, or reduces the severity of redness, thickening and swelling of the fingers or joints, pale fingers, numbness, tingling, pain, fever, fatigue, rash, loss of appetite, dry eyes, blurry vision, skin lesions, shortness of breath, or combinations thereof.
[0015] In specific embodiments, the administering step occurs systemically or locally. In specific embodiments, the administering step occurs locally to an area of the musculoskeletal system, the ocular surface, a neoplastic lesion, and/or a non-neoplastic lesion.
[0016] In specific embodiments, the one or more proton pump inhibitors are formulated alone or in combination with one or more other agents. In specific embodiments, the one or more proton pump inhibitors are administered prior to, during, and/or subsequent to administration of one or more other agents. In specific embodiments, the one or more other agents comprise one or more antifibrotic drugs, one or more appetite stimulants, one or more bronchodilators, one or more artificial tears, one or more corticosteroids, one or more antibiotics, one or more pain relievers, or combinations thereof.
[0017] In specific embodiments, the one or more proton pump inhibitors are formulated for local administration. In specific embodiments, the one or more proton pump inhibitors are formulated for topical administration. In specific embodiments, the one or more proton pump inhibitors are formulated for intraarticular and/or intratumoral injection. In specific embodiments, the one or more proton pump inhibitors are formulated for administration outside of the alimentary canal. In specific embodiments, the one or more proton pump inhibitors are formulated for administration other than for the stomach. In specific embodiments, the one or more proton pump inhibitors are formulated as a liquid, troche, suppository, cream, solid, tablet, pill, aerosol, gel, film, foam, ointment, paste, cream, syrup, powder, drops, suspension, or combinations thereof.
[0018] In specific embodiments, the one or more proton pump inhibitors is Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole, Haprazole, or combinations thereof. In specific embodiments, the concentration of the one or more proton pump inhibitors is in a range of l%-100% w/w. In specific embodiments, the concentration of the one or more proton pump inhibitors is not greater than 20% w/w.
[0019] In specific embodiments, the individual is or is not at risk of a medical condition involving uncontrolled inflammation and/or collagen accumulation, has or has not been tested for a medical condition involving uncontrolled inflammation and/or collagen accumulation, has or has not been diagnosed with a medical condition involving uncontrolled inflammation and/or collagen accumulation, and/or is or is not symptomatic for a medical condition involving uncontrolled inflammation and/or collagen accumulation.
[0020] In specific embodiments, the individual has or has not been tested for plasma concentrations of pro-inflammatory biomarkers, anti-inflammatory biomarkers, and/or collagen accumulation biomarkers, and/or has or has not been diagnosed with elevated plasma concentrations of pro-inflammatory biomarkers, depressed plasma concentrations of anti-
inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers.
[0021] In specific embodiments, the administering step treats, prevents, delays onset of, or reduces the severity of elevated plasma concentrations of pro-inflammatory biomarkers, depressed plasma concentrations of anti-inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers in the individual. In specific embodiments, said pro- inflammatory biomarkers are CRP, TNF-a, IL6, ILip, or combinations thereof, said antiinflammatory biomarkers are IL4, IL10, IL11, IL13, or combinations thereof, and said collagen accumulation biomarkers are TGFp, Col 1, Col 2, Col 3, Col 4, Col 5, laminin, fibronectin, or combinations thereof.
[0022] In specific embodiments, the individual has or is at risk for a medical condition involving uncontrolled inflammation and/or collagen accumulation selected from the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non- neoplastic lesions, or combinations thereof.
[0023] In specific embodiments, the individual has or is at risk for osteoarthritis; amyopathic dermatomyositis; inclusion body myositis; immune-mediated necrotizing myopathy; juvenile myositis; orbital myositis; antisynthetase syndrome; cryopyrin associated periodic syndromes; familial cold autoinflammatory syndrome; Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis; synovial fibrosis; arthro fibrosis; post-partial joint replacement; post-total joint replacement; tendinitis; fasciitis; systemic inflammatory response syndrome; extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’s disease; thyroid orbitopathy; rhinosinusitis; sepsis; diabetic neuropathy; chronic obstructive pulmonary disease; liver fibrosis; dry eye disease; chemotherapy-induced dry eye disease; uveitis, blepharitis; conjunctivitis; corneal infections; Meibomian gland dysfunction; ocular surface squamous neoplasia; corneal scarring; corneal abrasion, puncture or laceration;; pterygium; allergic eye diseases; ocular rosacea; ocular bum; ocular graft vs host disease; cataracts; glaucoma; Fuch’s endothelial dystrophy; age-related macular degeneration, glaucoma; steroid-induced increase in intra-ocular pressure; diabetic retinopathy; benign, pre-cancerous, or cancerous tumors; benign skin moles; skin tagscysts; nodules; polyps; bumps; patches; actinic keratosis; herpetic lesions; or combinations thereof.
[0024] In specific embodiments, the individual has redness, thickening and swelling of the fingers or joints, pale fingers, numbness, tingling, pain, fever, fatigue, rash, loss of appetite, dry eyes, blurry vision, skin lesions, shortness of breath, or combinations thereof.
[0025] In specific embodiments, the individual has or is at risk for a medical condition involving uncontrolled inflammation and/or collagen accumulation selected from the group consisting of musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non- neoplastic lesions, or combinations thereof, and wherein the one or more proton pump inhibitors is Esomeprazole that is topically formulated.
[0026] The foregoing has outlined rather broadly the features and technical advantages of the present disclosure in order that the detailed description that follows may be better understood. Additional features and advantages will be described hereinafter which form the subject of the claims herein. It should be appreciated by those skilled in the art that the conception and specific embodiments disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present designs. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope as set forth in the appended claims. The novel features which are believed to be characteristic of the designs disclosed herein, both as to the organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] FIGS. 1A-1B show the effect of esomeprazole on the regulation of collagen. Patient derived fibroblasts from scleroderma patients with limited (FIG. 1A) or diffuse (FIG. IB) were untreated (control), stimulated with only TGFB (TGF-B), or stimulated and treated with various concentrations of esomeprazole (TGF-B + Eso).
[0028] FIGS. 2A-2B show the effect of esomeprazole on body weight in mice with scleroderma. Scleroderma mouse models were untreated (Bleo control) or administered esomeprazole (Bleo + Eso) either topically (FIG. 2A) or systemically (FIG. 2B).
[0029] FIGS. 3A-3B show the effect of esomeprazole on organ weigh in mice with scleroderma. Untreated control mice (No bleo) or a mouse model of scleroderma were untreated (Bleo Control) or treated with esomeprazole (Bleo + Eso) either topically (FIG. 3A) or systemically (FIG. 3B).
DETAILED DESCRIPTION
I. Definitions
[0030] As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising", the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more. Still further, the terms “having”, “including”, “containing” and “comprising” are interchangeable and one of skill in the art is cognizant that these terms are open ended terms. Some embodiments of the disclosure may consist of or consist essentially of one or more elements, method steps, and/or methods of the disclosure. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Reference throughout this specification to “one embodiment,” “an embodiment,” “a particular embodiment,” “a related embodiment,” “a certain embodiment,” “an additional embodiment,” or “a further embodiment” or combinations thereof means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0031] The term "administered" or "administering", as used herein, refers to any method of providing a composition to an individual such that the composition has its intended effect on the individual. For example, one method of administering is by a direct mechanism such as, local tissue administration, transdermal patch, topical, etc.
[0032] The term "pharmaceutically" or "pharmacologically acceptable", as used herein, refer to molecular entities and compositions that do not produce unacceptable adverse, allergic, or other untoward reactions when administered to an animal or a human.
[0033] The term, "pharmaceutically acceptable carrier", as used herein, includes any and all solvents, or a dispersion medium including, but not limited to, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils, coatings, isotonic and absorption delaying agents, liposome, commercially available cleansers, and the like. Supplementary bioactive ingredients also can be incorporated into such carriers. Pharmaceutically acceptable carriers may comprise surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.
[0034] The term “preventing” as used herein refers to the methods that avert a medical condition from occurring in an individual, including averting the onset of at least one symptom of the medical condition.
[0035] The term “subject” or "individual", as used herein, refers to a human or animal that may or may not be housed in a medical facility and may be treated as an outpatient of a medical facility. The individual may be receiving one or more medical compositions via the internet. An individual may comprise any age of a human or non-human animal and therefore includes both adult and juveniles (z.e., children) and infants. It is not intended that the term "individual" connote a need for medical treatment, therefore, an individual may voluntarily or involuntarily be part of experimentation whether clinical or in support of basic science studies. The term “subject” or “individual” refers to any organism or animal subject that is an object of a method or material, including mammals, e.g., humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodents), horses, and transgenic non-human animals.
[0036] As used herein, the term “therapeutically effective amount” is synonymous with “effective amount”, “therapeutically effective dose”, and/or “effective dose” and refers to the amount of compound that will elicit the biological, cosmetic or clinical response being sought by the practitioner in an individual in need thereof. As one non-limiting example, an effective amount
is the amount sufficient to inhibit elevated pro-inflammatory or collagen accumulation biomarkers in an individual. As one non-limiting example, an effective amount is the amount sufficient to reduce elevated pro-inflammatory or collagen production biomarkers in an individual. As one non-limiting example, an effective amount is an amount sufficient to prevent uncontrolled inflammation and/or collagen accumulation in an individual. As another non-limiting example, an effective amount is an amount sufficient to reduce elevated inflammation and/or collagen accumulation in an individual. As another non-limiting example, an effective amount is an amount sufficient to prevent the symptoms of elevated inflammation and/or collagen accumulation in an individual. As another non-limiting example, an effective amount is an amount sufficient to ameliorate the symptoms of elevated inflammation and/or collagen accumulation in an individual.
[0037] The appropriate effective amount to be administered for a particular application of the disclosed methods can be determined by those skilled in the art, using the guidance provided herein. For example, an effective amount can be extrapolated from in vitro and in vivo assays as described in the present specification. One skilled in the art will recognize that the condition of the individual can be monitored throughout the course of therapy and that the effective amount of a compound or composition disclosed herein that is administered can be adjusted accordingly.
[0038] “Treatment,” “treat,” or “treating” means a method of reducing the effects of a disease or condition. Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms. The treatment can be any reduction from pre-treatment levels and can be but is not limited to the complete ablation of the disease, condition, or the symptoms of the disease or condition. Therefore, in the disclosed methods, treatment” can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or the disease progression, including reduction in the severity of at least one symptom of the disease. For example, a disclosed method for reducing inflammation in a subject is considered to be a treatment if there is a detectable reduction in the level of pro-inflammatory biomarkers in a subject when compared to pre-treatment levels in the same subject or control subjects. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. It is understood and herein contemplated that “treatment” does not necessarily refer to a cure of the disease or condition, but an improvement in the outlook of a disease or condition. In specific embodiments, treatment refers to the lessening in severity or extent of at least one symptom and may alternatively or in addition refer to a delay in the onset of at least one symptom.
II. Examples of Methods of Use
[0039] Proton pump inhibitors (PPIs) are FDA approved drugs for the treatment of gastric reflux. They are available in packages for systemic administration including in tablet and intravenous (IV) format. None of the PPIs have been approved for any indication outside of diseases characterized by abnormal secretion of gastric acidity. Embodiments of the disclosure concern the use of one or more proton pump inhibitors (PPIs) that are effective for a medical condition other than gastritis or gastritis-related purposes. In particular embodiments, the methods are for medical conditions directly or indirectly affected by uncontrolled inflammation and/or accumulated collagen, including but not limited to musculoskeletal conditions, ocular surface conditions, or non-neoplastic lesions.
[0040] The methods encompass medical conditions in which the ocular system or the skin, epidermis, dermis, and/or mucus membranes are affected because of exposure to one or more external conditions and/or in which the musculoskeletal system, the ocular surface, or the skin, epidermis, dermis, and/or mucus membranes are affected because of internal causes, such as a genetic or other cause including underlying conditions such as diabetes. In conditions in which the cause of the medical condition is external, the methods may be utilized prior to exposure to the external condition, during exposure to the external condition, and/or after exposure to the external condition. In conditions in which the cause is internal, such as genetic or other causes, the methods may be utilized prior to onset of a symptom of the condition and/or after onset of a symptom of the condition. In situations in which the individual is predisposed to have the medical condition, the individual may prophylactically be subject to methods of the disclosure. The methods include treatment or prevention for any inflammation-related and/or fibrosis-related medical condition. In specific embodiments, the methods provide therapy or prophylaxis to the musculoskeletal system, the ocular surface, skin, dermis, epidermis, and/or mucus membranes.
[0041] In specific embodiments, the external cause of the medical condition is environmental, such as exposure to chemical(s), radiation of any kind, and/or one or more allergens or pathogens. In specific embodiments, the internal cause of the medical condition is an infection, a trauma, an allergic reaction, an injury, and/or a genetic condition.
[0042] In certain embodiments, an individual is at risk of having a medical condition, such as a musculoskeletal disorder, ocular surface disorder, neoplastic lesion, non-neoplastic lesion, or combinations thereof. An individual may be at risk of a musculoskeletal disorder from poor
posture, repetitive movements, forceful movements (including heavy lifting or excessive pressure), vibrations, overexertion, work-related activities, awkward postures, stress, obesity, smoking, aging, or a combination thereof. An individual may be at risk of an ocular surface disorder from having diabetes, having glaucoma, being over- medicated, advancing age, gender, a dry environment, smoking, smoke exposure, having connective tissue disorder, a vitamin A deficiency, a prior eye surgery, having rosacea, or a combination thereof. An individual may be at risk of a neoplastic lesion from advancing age, a personal or family history of cancer, using tobacco, obesity, using alcohol, certain viral infections (such as human papillomavirus), exposure to carcinogens, exposure to radiation, or a combination thereof. An individual may be at risk of a non-neoplastic lesion from congenital issues, degenerative issues, inflammation, adaptive changes, reparative changes, or a combination thereof.
[0043] In certain embodiments, the individual administered the compositions disclosed herein, including any PPI disclosed herein, has, or is suspected of having, one or more treatment related injuries. In some embodiments, the individual is administered any of the compositions disclosed herein to prevent or reduce a treatment related injury. The injury may be from any treatment, such as a cancer treatment. The treatment may comprise a tyrosine kinase inhibitor (TKI). The injury may comprise any lung injury, such as a treatment- induced lung injury. In some embodiments, the individual has, or is suspected of having, interstitial lung disease, pneumonitis, and/or TKI-induced lung disease. In some embodiments, the individual is administered any composition disclosed herein to prevent or reduce interstitial lung disease, pneumonitis, and/or TKI-induced lung disease. In some embodiments, the individual has, or is suspected of having, an inflammatory condition. In some embodiments, the individual is administered any composition disclosed herein to prevent or reduce an inflammatory condition.
[0044] In some embodiments, an individual is tested for a medical condition in order to determine whether the individual should be treated, including treated with any methods or compositions disclosed herein. The medical condition may involve uncontrolled inflammation, such as any autoimmune disease, cancer, heart disease, or degenerative disease. The medical condition may involve collagen accumulation. The individual may be tested for inflammation. In some embodiments, the individual is tested for one or more biomarkers of inflammation, such as C-reactive protein. The C-reactive protein in an individual to be treated may be more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 mg/L or more. In some embodiments, the erythrocyte sedimentation rate (ESR) or plasma viscosity (PV) are tested. The ESR in an individual to be
treated may be more than 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, mm/hr or more. The PV in an individual to be treated may be outside a normal range, including outside 1.10-1.30 mPa or outside of 1.50-1.72 mPa. In some embodiments, collagen accumulation is tested by immunohistochemistry, such as by trichrome staining or using molecules reactive or capable of binding to any collagen molecule. The individual may be tested for plasma concentrations of pro-inflammatory biomarkers, anti-inflammatory biomarkers, and/or collagen accumulation biomarkers. One skilled in the art is able to determine an appropriate test and the appropriate resulting values for determining whether an individual should be treated. In specific embodiments, an additional treatment or preventative therapy may be provided in combination with the disclosed treatment. In specific embodiments, the additional treatment or preventative therapy is for pain, allergy, infection, inflammation, shortness of breath, and/or bleeding.
[0045] Alternatively, the disclosed treatment may precede, follow, or both, an additional treatment or preventative therapy by intervals ranging from minutes to weeks to months. In embodiments where the disclosed treatment and the additional agent are provided separately to an individual, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the disclosed treatment and the additional agent would still be able to exert an advantageously combined effect against the medical condition. In such instances, it is contemplated that one may deliver both modalities within about 12-24 h of each other and, in some embodiments, within about 6-12 h of each other. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) to several months (from 1-12), any subrange therein, and so forth, lapse between the respective administrations.
[0046] Various combinations may be employed, for example, wherein the disclosed treatment is “A” and the secondary additional treatment or preventative is “B”:
A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B
B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A
B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A
[0047] Administration of the disclosed treatment to a patient will follow general protocols for the administration of drugs, taking into account the toxicity, if any, of the molecule. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that
various standard therapies, as well as surgical intervention, may be applied in combination with the described therapy.
III. Examples of PPIs and Compositions Thereof
[0048] PPIs are normally utilized for gastric conditions, but this disclosure encompasses reformulation of their use for conditions other than gastric conditions to formulations useful for one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation. This characteristic of PPIs is devoid of the indication (z.e., treatment of gastritis) for which they are FDA- approved. PPIs directly regulate many of the pro -inflammatory and/or collagen accumulation biomarkers generated in response to many medical conditions, as encompassed herein. Many of these PPI-regulated cytokines are reported to be upregulated in musculoskeletal conditions, ocular surface conditions, and/or non-neoplastic lesions, for example.
[0049] Embodiments of the disclosure include one or more PPIs for treatment of one or more medical conditions involving uncontrolled inflammation and/or collagen accumulation. The PPIs may be formulated into any kind of composition suitable for the treatment or prevention required. The PPIs may be formulated for local or systemic administration, although in particular embodiments the administration is not for a gastric application. When more than one PPI is provided to an individual, they may or may not be formulated in the same composition.
[0050] As a specific example, the present disclosure demonstrates the direct application of topical PPI (esomeprazole) cream to the skin to prevent and/or treat collagen accumulation and confirms control of collagen secretion and wound healing in vitro and in an animal model of scleroderma. In accordance, the PPIs can be reformulated in various preparations including cream, liquid, troche, and suppository to prevent and/or treat collagen accumulation and to promote wound healing, as examples.
[0051] In particular embodiments, the PPI is Esomeprazole, Omeprazole, Lansoprazole, Dexlansoprazole, Pantoprazole, Rabeprazole, Ilaprazole, or a combination thereof. When an individual is provided multiple PPIs, they may or may not be formulated in different types of formulations, regardless of the regimen provided to the individual.
[0052] In particular embodiments, the one or more PPIs are formulated in a composition with one or more other agents for a therapeutic or other purpose. Examples include one or more antifibrotic drugs, appetite stimulants, bronchodilators, artificial tears, one or more corticosteroids,
one or more antibiotics, one or more pain relievers, or a combination thereof. One particular embodiment of a composition comprises one or more PPIs with lidocaine that for example may be used to simultaneously relieve pain and treat the inflammatory and/or fibrotic condition(s).
[0053] Pharmaceutical compositions of the present disclosure comprise an effective amount of one or more PPIs dissolved or dispersed in a pharmaceutically acceptable carrier. The preparation of a pharmaceutical composition that contains at least one PPI or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington: The Science and Practice of Pharmacy, 21st Ed. Lippincott Williams and Wilkins, 2005, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.
[0054] The one or more PPIs may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection. The one or more PPIs can be administered topically, locally, intradermally, transdermally, subcutaneously, mucosally, in creams or gels, and so forth, although in certain cases the PPIs are administered intravenously, intrathecally, intraarterially, intratumorally, intraarticularly, intraperitoneally, sublingually, intranasally, intravaginally, intrarectally, intramuscularly, orally, by inhalation (e.g., aerosol inhalation), injection (intraarticular, subcutaneous, intratumoral, etc.), as eye drops, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference).
[0055] The one or more PPIs may be formulated into a composition in a free base, neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, magnesium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation
and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as formulated for parenteral administrations such as injectable solutions, or aerosols for delivery to the lungs, or formulated for alimentary administrations such as drug release capsules and the like.
[0056] Further in accordance with the present disclosure, the composition of the present disclosure suitable for administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent. The carrier should be assimilable and includes liquid, semi-solid, pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of the composition contained therein, its use in administrable composition for use in practicing the methods of the present disclosure is appropriate. Examples of carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof. The composition may also comprise various antioxidants, including but not limited to sodium metabisulfite, glutathione or N-acetyl cysteine, to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
[0057] In accordance with the present disclosure, the composition may be combined with the carrier in any convenient and practical manner, i.e., by solution, suspension, emulsification, admixture, encapsulation, absorption and the like. Such procedures are routine for those skilled in the art.
[0058] In a specific embodiment of the present disclosure, the composition is combined or mixed thoroughly with a semi-solid or solid carrier. The mixing can be carried out in any convenient manner such as grinding. Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, e.g., denaturation in the stomach. Examples of stabilizers for use in the composition include buffers, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.
[0059] In further embodiments, the present disclosure may encompass the use of a pharmaceutical lipid vehicle compositions that include one or more PPIs, one or more lipids, and an aqueous solvent. As used herein, the term “lipid” will be defined to include any of a broad
range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds are well known to those of skill in the art, and as the term “lipid” is used herein, it is not limited to any particular structure. Examples include compounds which contain long-chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally occurring or synthetic (/'.<?. , designed or produced by man). However, a lipid is usually a biological substance. Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof. Of course, compounds other than those specifically described herein that are understood by one of skill in the art as lipids are also encompassed by the compositions and methods of the present disclosure.
[0060] One of ordinary skill in the art would be familiar with the range of techniques that can be employed for dispersing a composition in a lipid vehicle. For example, the PPI(s) may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art. The dispersion may or may not result in the formation of liposomes.
[0061] The actual dosage amount of a composition of the present disclosure administered to an individual can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, and/or on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the individual. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual.
[0062] In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, the active compound may comprise between about 1% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage
will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
[0063] In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 milligram /kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 milligram /kg/body weight to about 100 milligram /kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above.
[0064] In certain embodiments, the PPI is formulated in a particular concentration in a composition. In specific embodiments, the PPI is formulated in a range of l%-100% w/w, or any range derivable therein. In specific cases, the PPI is formulated in a range of l%-100%, 1 %-75%, l%-50%, l%-25%, 10%-100%, 10%-75%, 10%-50%, 25%-100%, 25%-75%, 25%-50%, 1%- 20%, 1%-18%, 1%-16%, 1%-15%, 1%-12%, l%-10%, l%-8%, l%-6%, l%-5%, l%-4%, 1%- 3%, l%-2%, 2%-5%, 2%-4%, 2%-3%, 3%-5%, 3%-4%, 4%-5%, 5%-20%, 5%-15%, 5%-10%, 10%-20%, 10%- 15%, 12%-15%, 12%-20% w/w. The PPI may be formulated in a concentration of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% w/w, in some cases.
[0065] In particular embodiments, the concentration of proton pump inhibitor is not greater than 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 20%, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% w/w.
A. Parenteral Compositions and Formulations
[0066] In further embodiments, one or more PPIs may be administered via a parenteral route. As used herein, the term “parenteral” includes routes that bypass the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered for example, but not limited to intravenously, intradermally, intramuscularly, intraarterially, intratumorally, intraarticularly, intrathecally, subcutaneous, or intraperitoneally such as described in U.S. Pat. Nos. 6,7537,514, 6,613,308, 5,466,468, 5,543,158; 5,641,515; and 5,399,363 (each specifically incorporated herein by reference in its entirety).
[0067] Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Patent 5,466,468, specifically incorporated herein by reference in its entirety). In certain embodiments, the form must be sterile and must be fluid to the extent that easy injectability exists. In certain embodiments, it must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (z.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0068] For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present
disclosure. For example, one dosage may be dissolved in isotonic NaCl solution and either added hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards.
[0069] Sterile injectable solutions may be prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation include vacuum-drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. A powdered composition may be combined with a liquid carrier such as, e.g., water or a saline solution, with or without a stabilizing agent.
B. Alimentary Compositions and Formulations
[0070] Although, in some embodiments, the PPI(s) are formulated for parenteral administration, in an alternative embodiment of the present disclosure, the one or more PPIs may be formulated to be administered via an alimentary route. Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft- shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
[0071] In certain embodiments, the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz etal., 1997; Hwang etal., 1998; U.S. Pat. Nos. 5,641,515; 5,580,579 and 5,792, 451, each specifically incorporated herein by reference in its entirety). The
tablets, troches, pills, capsules and the like may also contain the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, corn starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. When the dosage form is a capsule, it may contain, in addition to materials of the above type, carriers such as a liquid carrier. Gelatin capsules, tablets, or pills may be enterically coated. Enteric coatings prevent denaturation of the composition in the stomach or upper bowel where the pH is acidic. See, e.g., U.S. Pat. No. 5,629,001. Upon reaching the small intestines, the basic pH therein dissolves the coating and permits the composition to be released and absorbed by specialized cells, e.g., epithelial enterocytes and Peyer's patch M cells. A syrup of elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.
[0072] For oral administration, the compositions of the present disclosure may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, mucoadhesive agent, oral spray, or sublingual orally-administered formulation. For example, a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically- effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively, the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.
[0073] Additional formulations that are suitable for other modes of alimentary administration include suppositories. Suppositories are solid dosage forms of various weights and shapes, usually medicated, for insertion into the rectum. After insertion, suppositories soften, melt or dissolve in the cavity fluids. In general, for suppositories, traditional carriers may include, for example, polyalkylene glycols, triglycerides or combinations thereof. In certain embodiments, suppositories may be formed from mixtures containing, for example, the active ingredient in the range of about 0.5% to about 10%, and preferably about 1% to about 2%.
C. Miscellaneous Pharmaceutical Compositions and Formulations
[0074] In other preferred embodiments of the disclosure, the active compound PPI(s) may be formulated for administration via various miscellaneous routes, for example, topical (/'.<?., transdermal with or without the aid of patches or bandages) administration, mucosal administration (intranasal, oral, vaginal, etc.) and/or inhalation.
[0075] Pharmaceutical compositions for topical administration may include the active compound formulated for a medicated application such as an ointment, paste, cream, gel, or powder. Ointments include all oleaginous, adsorption, emulsion and water-solubility based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only. Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones and luarocapram. Possible bases for compositions for topical application include polyethylene glycol, lanolin, cold cream and petrolatum as well as any other suitable absorption, emulsion or water-soluble ointment base. Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the active ingredient and provide for a homogenous mixture. Transdermal administration of the present disclosure may also comprise the use of a "patch". For example, the patch may supply one or more active substances at a predetermined rate and in a continuous manner over a fixed period of time.
[0076] In certain embodiments, the pharmaceutical compositions may be delivered by eye drops, eye suspensions, eye gels, eye ointments, intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in its entirety). Likewise, the delivery of drugs using intranasal
microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725, 871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts. Likewise, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety).
[0077] The term aerosol refers to a colloidal system of finely divided solid of liquid particles dispersed in a liquefied or pressurized gas propellant. The typical aerosol of the present disclosure for inhalation will consist of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent. Suitable propellants include hydrocarbons and hydrocarbon ethers. Suitable containers will vary according to the pressure requirements of the propellant. Administration of the aerosol will vary according to subject’s age, weight and the severity and response of the symptoms.
IV. Kits of the Disclosure
[0078] Any of the PPI compositions described herein may be comprised in a kit. In a nonlimiting example, one or more PPIs may be comprised in a kit. The kits will thus comprise, in suitable container means, a PPI(s) and a lipid, and/or an additional agent of the present disclosure. The one or more PPI compositions may be formulated as a liquid, troche, suppository, cream, solid, tablet, pill, aerosol, gel, film, foam, ointment, paste, cream, syrup, powder, or combination thereof, for example. In specific embodiments, one or more PPI compositions formulated for use as prevention or treatment of indications encompassed herein and also may be provided in a kit with one or more antifibrotic drugs, appetite stimulants, bronchodilators, artificial tears, one or more corticosteroids, one or more antibiotics, one or more pain relievers, or a combination thereof. In some cases, a first PPI is packaged with a first other therapeutic while a second packaging comprises a second PPI packaged with a second other therapeutic. In such cases when a PPI and a pain reliever(s) and optionally another therapeutic are packaged in the same package they may be housed within different containers within the package.
[0079] The kits may comprise a suitably aliquoted PPIs, lipid and/or additional agent compositions of the present disclosure. The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in
the kit, the kit also will generally contain a second, third or other additional container or compartment into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present disclosure also will typically include a means for containing the one or more PPIs, lipid, additional agent, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.
[0080] However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.
[0081] The container means will generally include at least one vial, test tube, flask, bottle, syringe and/or other container means or compartment in which the formulation(s) are placed, preferably, suitably allocated. The kits may also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.
[0082] The kits of the present disclosure will also typically include a means for containing the vials in close confinement for commercial sale, such as, e.g., injection and/or blow-molded plastic containers into which the desired vials are retained.
EXAMPLES
[0083] The following examples are included to demonstrate particular embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques that function well in the practice of the disclosure, and thus can be considered to constitute particular modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.
EXAMPLE 1
PPIs UPREGULATING ANTI-INFLAMMATORY CYTOKINES
[0084] In a gene expression study for pro-inflammatory cytokines, primary human endothelial cells are being exposed to either bleomycin (25 pg/ml) to induce inflammation or a vehicle control. Primary human endothelial cells are also being exposed to esomeprazole (1-100 pM) to test the PPI for anti-inflammatory effect or a vehicle control. The study is confirming that the PPI esomeprazole is significantly (p<0.05) upregulating expression of IL4, IL10, IL11 and IL13 in primary human endothelial cells versus the control.
EXAMPLE 2
PPIs REDUCING PLASMA LEVELS OF PRO-INFLAMMATORY BIOMARKERS
[0085] In certain aspects, in a randomized clinical trial, levels of pro-inflammatory biomarkers are being studied in subjects diagnosed with inflammation condition before and after proton pump inhibitor supplementation or placebo, for 14-21 days. A group of subjects without inflammation is serving as a control. Levels of pro-inflammatory biomarkers are being measured in all subjects as levels of CRP, TNFa, IL6, and/or ILip in blood. Results are showing that levels of pro-inflammatory biomarkers are improving only in patients with inflammation who receive proton pump inhibitor supplementation, and not in patients with inflammation who receive placebo. Further analyses are showing that the levels of pro-inflammatory biomarkers in subjects with inflammation are decreasing to approximate values in subjects without inflammation.
EXAMPLE 3
PPIs REDUCE PLASMA LEVELS OF COLLAGEN ACCUMULATION BIOMARKERS
[0086] In certain aspects, in a randomized clinical trial, levels of collagen accumulation biomarkers are being studied in subjects diagnosed with collagen accumulation before and after proton pump inhibitor supplementation or placebo, for 14-21 days. A group of subjects without collagen accumulation is serving as a control. Levels of collagen accumulation biomarkers are being measured in all subjects as levels of TGFp, Collagen (Col) types 1, 2, 3, 4, 5, fibronectin, and/or laminin in blood. Results are showing that levels of collagen accumulation biomarkers are decreasing only in patients with collagen accumulation who receive proton pump inhibitor
supplementation, and not in patients with collagen accumulation who receive placebo. Further analyses are showing that the levels of collagen accumulation biomarkers in subjects with fibrosis are decreasing to approximate values in subjects without fibrosis.
EXAMPLE 4
PPIs INCREASE PLASMA LEVELS OF ANTI-INFLAMMATORY BIOMARKERS
[0087] In certain aspects, in a randomized clinical trial, levels of anti-inflammatory biomarkers are being studied in subjects diagnosed with inflammation before and after proton pump inhibitor supplementation or placebo, for 14-21 days. A group of subjects without inflammation is serving as a control. Levels of anti-inflammatory biomarkers are being measured in all subjects as levels of IL4, IL10, IL11, and IL13 in blood. Results are showing that levels of anti-inflammatory biomarkers are increasing only in patients with inflammation who receive proton pump inhibitor supplementation, and not in patients with inflammation who receive placebo. Further analyses are showing that the levels of anti-inflammatory biomarkers in subjects with inflammation are increasing to approximate values in subjects without inflammation.
EXAMPLE 5
ESOMEPRAZOLE REGULATION OF COLLAGEN PRODUCTION
[0088] FIGS. 1A and IB provide an example of a particular embodiment of the disclosure wherein the PPI esomeprazole favorably regulates collagen production in scleroderma patient- derived skin fibroblasts from limited (FIG. 1A) and diffuse (FIG. IB) disease compared to TGFP- stimulated cells that are not treated with the drug.
EXAMPLE 6
ESOMEPRAZOLE IMPROVES HEALTH IN A MOUSE MODEL OF SCLERODERMA
[0089] FIGS. 2A-2B provide an example of a particular embodiment of the disclosure wherein the PPI esomeprazole, applied topically at 2% (FIG. 2A) or systemically at 60 mg/kg (FIG. 2B), improves the overall health in a mouse model of scleroderma as shown by the return of body weight to baseline levels compared to control animals not treated with esomeprazole.
EXAMPLE 7
ESOMEPRAZOLE DOES NOT AFFECT ORGAN WEIGHT
[0090] FIGS. 3A-3B provide an example of a particular embodiment of the disclosure wherein the PPI esomeprazole, applied topically at 2% (FIG. 3A) or systemically at 60 mg/kg (FIG. 3B), does not adversely affect organ weight in a mouse model of scleroderma as shown by the lack of difference in the weight of the lungs, heart, and kidneys compared to control animals not treated with esomeprazole.
EXAMPLE 8
ASSAYS OF ESOMEPRAZOLE
[0091] In the present disclosure, examples of molecular, cell biological, and animal testing show that PPIs regulate processes involved in tissue inflammation and/or collagen overproduction. In an in vitro assay, the present disclosure confirmed that the PPI esomeprazole inhibited pro- inflammatory cytokines in primary human endothelial cells and simultaneously controls several pro-inflammatory molecules including TNFa, ILip, and IL6. The present disclosure further confirmed that PPIs controlled the proliferation of primary human fibroblasts (cells that are primarily responsible for collagen production) and the deposition of collagen. In a bioinformatics study, the present disclosure confirmed that PPIs controlled a network of extracellular matrix proteins including several collagen types, and induced wound healing related proteins. In an in vivo study in an animal model of scleroderma, the present disclosure confirmed that PPIs controlled the degree of collagen deposition and accelerated wound healing.
[0092] In certain aspects, in an in vitro assay, the PPI esomeprazole is decreasing collagen accumulation biomarkers in primary human endothelial cells and simultaneously decreasing concentrations of several collagen accumulation molecules including TGFp, Collagen 1, 2, 3, 4, 5. In certain aspects, in an in vitro assay, the PPI esomeprazole is increasing anti-inflammatory cytokines in primary human endothelial cells and simultaneously increasing concentrations of several anti-inflammatory molecules including IL4, IL10, IL11, and/or IL13.
[0093] In certain aspects, in a randomized clinical trial, proton pump inhibitor supplementation is reducing levels of pro-inflammatory biomarkers versus a placebo in subjects diagnosed with inflammation. In certain aspects, in a randomized clinical trial, proton pump
inhibitor supplementation is reducing levels of collagen accumulation biomarkers versus a placebo in subjects diagnosed with collagen accumulation. In certain aspects, in a randomized clinical trial, proton pump inhibitor supplementation is increasing levels of anti-inflammatory biomarkers versus a placebo in subjects diagnosed with inflammation.
[0094] Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the design as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the present disclosure, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the present disclosure. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.
Claims
1. A method of treating, preventing, delaying onset of, or reducing severity of one or more medical conditions in an individual in need thereof, comprising the step of administering to the individual an effective amount of one or more proton pump inhibitors wherein the one or more medical conditions comprise musculoskeletal disorders, ocular surface disorders, neoplastic lesions, non-neoplastic lesions, or combinations thereof.
2. The method of claim 1, wherein the administering step treats, prevents, delays onset of, or reduces the severity of uncontrolled inflammation and/or collagen accumulation in the individual.
3. The method of claim 1 or 2, wherein the administering step treats, prevents, delays onset of, or reduces the severity of redness, thickening and swelling of the fingers or joints, pale fingers, numbness, tingling, pain, fever, fatigue, rash, loss of appetite, dry eyes, blurry vision, skin lesions, shortness of breath, or combinations thereof.
4. The method of any one of claims 1-3, wherein the administering step occurs systemically or locally.
5. The method of any one of claims 1-4, wherein the administering step occurs locally to an area of the musculoskeletal system, the ocular surface, a neoplastic lesion, and/or a non-neoplastic lesion.
6. The method of any one of claims 1-5, wherein the one or more proton pump inhibitors are formulated alone or in combination with one or more other agents.
7. The method of any one of claims 1-6, wherein the one or more proton pump inhibitors are administered prior to, during, and/or subsequent to administration of one or more other agents.
8. The method of claim 6 or 7, wherein said one or more other agents comprise one or more antifibrotic drugs, one or more appetite stimulants, one or more bronchodilators, one or more artificial tears, one or more corticosteroids, one or more antibiotics, one or more pain relievers, or combinations thereof.
- 29 -
9. The method of any one of claims 1-8, wherein the one or more proton pump inhibitors are formulated for local administration.
10. The method of any one of claims 1-9, wherein the one or more proton pump inhibitors are formulated for topical administration.
11. The method of any one of claims 1-10, wherein the one or more proton pump inhibitors are formulated for intraarticular and/or intratumoral injection.
12. The method of any one of claims 1-11, wherein the one or more proton pump inhibitors are formulated for administration outside of the alimentary canal.
13. The method of any one of claims 1-12, wherein the one or more proton pump inhibitors are formulated for administration other than for the stomach.
14. The method of any one of claims 1-13, wherein the one or more proton pump inhibitors are formulated as a liquid, troche, suppository, cream, solid, tablet, pill, aerosol, gel, film, foam, ointment, paste, cream, syrup, powder, drops, suspension, or combinations thereof.
15. The method of any one of claims 1-14, wherein the one or more proton pump inhibitors comprises Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole, Ilaprazole, or combinations thereof.
16. The method of any one of claims 1-15, wherein the concentration of the one or more proton pump inhibitors is in a range of l%-100% w/w.
17. The method of any one of claims 1-16, wherein the concentration of the one or more proton pump inhibitors is not greater than 20% w/w.
18. The method of any one of claims 1-17, wherein the individual is at risk of a medical condition involving uncontrolled inflammation and/or collagen accumulation, has been tested for a medical condition involving uncontrolled inflammation and/or collagen accumulation, has been diagnosed with a medical condition involving uncontrolled inflammation and/or collagen accumulation, and/or is symptomatic for a medical condition involving uncontrolled inflammation and/or collagen accumulation.
- 30 -
19. The method of any one of claims 1-18, wherein the individual has been tested for plasma concentrations of pro-inflammatory biomarkers, anti-inflammatory biomarkers, and/or collagen accumulation biomarkers, and/or has been diagnosed with elevated plasma concentrations of pro- inflammatory biomarkers, depressed plasma concentrations of anti-inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers.
20. The method of any one of claims 1-19, wherein the administering step treats, prevents, delays onset of, or reduces the severity of elevated plasma concentrations of pro-inflammatory biomarkers, depressed plasma concentrations of anti-inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers in the individual.
21. The method of claim 20, wherein said pro-inflammatory biomarkers comprise CRP, TNF- a, IL6, ILip, or combinations thereof, wherein said anti-inflammatory biomarkers comprise IL4, IL10, IL11, IL13, or combinations thereof, and/or wherein said collagen accumulation biomarkers comprise TGFp, Col 1, Col 2, Col 3, Col 4, Col 5, laminin, fibronectin, or combinations thereof.
22. The method of any one of claims 1-21, wherein the individual has or is at risk for osteoarthritis; amyopathic dermatomyositis; inclusion body myositis; immune-mediated necrotizing myopathy; juvenile myositis; orbital myositis; antisynthetase syndrome; cryopyrin associated periodic syndromes; familial cold autoinflammatory syndrome; Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis; synovial fibrosis; arthrofibrosis; post-partial joint replacement; post-total joint replacement; tendinitis; fasciitis; systemic inflammatory response syndrome; extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’s disease; thyroid orbitopathy; rhinosinusitis; sepsis; diabetic neuropathy; chronic obstructive pulmonary disease; liver fibrosis; dry eye disease; chemotherapy-induced dry eye disease; uveitis, blepharitis; conjunctivitis; corneal infections; Meibomian gland dysfunction; ocular surface squamous neoplasia; corneal scarring; corneal abrasion, puncture or laceration; pterygium; allergic eye diseases; ocular rosacea; ocular bum; ocular graft vs host disease; cataracts; glaucoma; Fuch’s endothelial dystrophy; age-related macular degeneration, glaucoma; steroid-induced increase in intra-ocular pressure; diabetic retinopathy; benign, pre-cancerous, or cancerous tumors; benign skin moles; skin tags; melanoma and non-melanoma skin cancers; cysts; nodules; polyps; bumps; patches; actinic keratosis; herpetic lesions; or combinations thereof.
23. The method of any one of claims 1-22, wherein the individual has redness, thickening and swelling of the fingers or joints, pale fingers, numbness, tingling, pain, fever, fatigue, rash, loss of appetite, dry eyes, blurry vision, skin lesions, shortness of breath, or combinations thereof.
24. The method of any one of claims 1-23 wherein the one or more proton pump inhibitors is Esomeprazole that is topically formulated.
25. A method of regulating collagen in an individual comprising the step of administering to the individual an effective amount of one or more proton pump inhibitors.
26. The method of claim 25, wherein the administering step occurs systemically or locally.
27. The method of claim 25 or 26, wherein the administering step occurs locally to an area of the musculoskeletal system, the ocular surface, a neoplastic lesion, and/or a non-neoplastic lesion.
28. The method of any one of claims 25-27, wherein the one or more proton pump inhibitors are formulated alone or in combination with one or more other agents.
29. The method of any one of claims 25-28, wherein the one or more proton pump inhibitors are administered prior to, during, and/or subsequent to administration of one or more other agents.
30. The method of claim 28 or 29, wherein said one or more other agents comprise one or more antifibrotic drugs, one or more appetite stimulants, one or more bronchodilators, one or more artificial tears, one or more corticosteroids, one or more antibiotics, one or more pain relievers, or combinations thereof.
31. The method of any one of claims 25-30, wherein the one or more proton pump inhibitors are formulated for local administration.
32. The method of any one of claims 25-31, wherein the one or more proton pump inhibitors are formulated for topical administration.
33. The method of any one of claims 25-32, wherein the one or more proton pump inhibitors are formulated for intraarticular injection.
34. The method of any one of claims 25-33, wherein the one or more proton pump inhibitors are formulated for administration outside of the alimentary canal.
35. The method of any one of claims 25-34, wherein the one or more proton pump inhibitors are formulated for administration other than for the stomach.
36. The method of any one of claims 25-35, wherein the one or more proton pump inhibitors are formulated as a liquid, troche, suppository, cream, solid, tablet, pill, aerosol, gel, film, foam, ointment, paste, cream, syrup, powder, drops, suspension, or combinations thereof.
37. The method of any one of claims 25-36, wherein the one or more proton pump inhibitors comprises Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole, Ilaprazole, or combinations thereof.
38. The method of any one of claims 25-37, wherein the concentration of the one or more proton pump inhibitors is in a range of l%-100% w/w.
39. The method of any one of claims 25-38, wherein the concentration of the one or more proton pump inhibitors is not greater than 20% w/w.
40. The method of any one of claims 25-39, wherein the individual is at risk of a medical condition involving uncontrolled inflammation and/or collagen accumulation, has been tested for a medical condition involving uncontrolled inflammation and/or collagen accumulation, has been diagnosed with a medical condition involving uncontrolled inflammation and/or collagen accumulation, and/or is symptomatic for a medical condition involving uncontrolled inflammation and/or collagen accumulation.
41. The method of any one of claims 25-40, wherein the individual has been tested for plasma concentrations of pro-inflammatory biomarkers, anti-inflammatory biomarkers, and/or collagen accumulation biomarkers, and/or has been diagnosed with elevated plasma concentrations of pro- inflammatory biomarkers, depressed plasma concentrations of anti-inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers.
42. The method of any one of claims 25-41, wherein the administering step treats, prevents, delays onset of, or reduces the severity of elevated plasma concentrations of pro-inflammatory biomarkers, depressed plasma concentrations of anti-inflammatory biomarkers, and/or elevated plasma concentrations of collagen accumulation biomarkers in the individual.
- 33 -
43. The method of claim 42, wherein said pro-inflammatory biomarkers comprise CRP, TNF- a, IL6, ILip, or combinations thereof, wherein said anti-inflammatory biomarkers comprise IL4, IL10, IL11, IL13, or combinations thereof, and/or wherein said collagen accumulation biomarkers comprise TGFp, Col 1, Col 2, Col 3, Col 4, Col 5, laminin, fibronectin, or combinations thereof.
44. The method of any one of claims 25-43, wherein the individual has or is at risk for osteoarthritis; amyopathic dermatomyositis; inclusion body myositis; immune-mediated necrotizing myopathy; juvenile myositis; orbital myositis; antisynthetase syndrome; cryopyrin associated periodic syndromes; familial cold autoinflammatory syndrome; Muckle-Wells syndrome; sarcoidosis; adult onset Still’s disease; polychondrosis; polymyalgia; fibromyalgia; osteomyelitis; bursitis; synovitis; synovial fibrosis; arthrofibrosis; post-partial joint replacement; post-total joint replacement; tendinitis; fasciitis; systemic inflammatory response syndrome; extraintestinal manifestations of inflammatory bowel disease, ulcerative colitis, or Crohn’s disease; thyroid orbitopathy; rhinosinusitis; sepsis; diabetic neuropathy; chronic obstructive pulmonary disease; liver fibrosis; dry eye disease; chemotherapy-induced dry eye disease; uveitis, blepharitis; conjunctivitis; corneal infections; Meibomian gland dysfunction; ocular surface squamous neoplasia; corneal scarring; corneal abrasion, puncture or laceration; pterygium; allergic eye diseases; ocular rosacea; ocular bum; ocular graft vs host disease; cataracts; glaucoma; Fuch’s endothelial dystrophy; age-related macular degeneration, glaucoma; steroid-induced increase in intra-ocular pressure; diabetic retinopathy; benign, pre-cancerous, or cancerous tumors; benign skin moles; skin tags; melanoma and non-melanoma skin cancers; cysts; nodules; polyps; bumps; patches; actinic keratosis; herpetic lesions; or combinations thereof.
45. The method of any one of claims 25-44, wherein the individual has redness, thickening and swelling of the fingers or joints, pale fingers, numbness, tingling, pain, fever, fatigue, rash, loss of appetite, dry eyes, blurry vision, skin lesions, shortness of breath, or combinations thereof.
46. The method of any one of claims 25-45 wherein the one or more proton pump inhibitors is Esomeprazole that is topically formulated.
- 34 -
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063107948P | 2020-10-30 | 2020-10-30 | |
US63/107,948 | 2020-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022094602A1 true WO2022094602A1 (en) | 2022-05-05 |
Family
ID=81384436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/072126 WO2022094602A1 (en) | 2020-10-30 | 2021-10-29 | Proton pump inhibitors for the treatment of diseases characterized by inflammation and/or collagen accumulation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022094602A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016189562A1 (en) * | 2015-05-26 | 2016-12-01 | Irccs Azienda Ospedaliera Universitaria San Martino-Ist-Istituto Nazionale Per La Ricerca Sul Cancro | Proton pump inhibitors for use in anti-inflammatory therapy |
WO2019169175A1 (en) * | 2018-02-28 | 2019-09-06 | Baylor College Of Medicine | Proton pump inhibitors and methods of use in chemoradiation-induced tissue inflammation and scarring |
-
2021
- 2021-10-29 WO PCT/US2021/072126 patent/WO2022094602A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016189562A1 (en) * | 2015-05-26 | 2016-12-01 | Irccs Azienda Ospedaliera Universitaria San Martino-Ist-Istituto Nazionale Per La Ricerca Sul Cancro | Proton pump inhibitors for use in anti-inflammatory therapy |
WO2019169175A1 (en) * | 2018-02-28 | 2019-09-06 | Baylor College Of Medicine | Proton pump inhibitors and methods of use in chemoradiation-induced tissue inflammation and scarring |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3261646B1 (en) | Reduction of adipose tissue | |
JP7475395B2 (en) | Compositions and methods of using nintedanib to treat ocular diseases involving abnormal neovascularization | |
KR101453601B1 (en) | Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection | |
JP7443443B2 (en) | Compositions and kits for treating joints | |
CZ284928B6 (en) | The use of riluzol or pharmaceutically acceptable salts thereof for preparing medicaments | |
JP4987209B2 (en) | Use of biguanide derivatives for the manufacture of pharmaceuticals with scarring action | |
US7259180B2 (en) | Methods and compositions for treatment of macular and retinal disease | |
KR20090123863A (en) | Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes | |
US12029725B2 (en) | Method for treating osteoarthritis pain by administering resiniferatoxin | |
HUT74462A (en) | Compositions for inhibition of angiogenesis, containing hyaluronic acid and nonsteroidal anti-inflammatory agents | |
CN115463118A (en) | Application of honokiol in preparing medicine for treating or preventing capillary hemangioma | |
WO2022094602A1 (en) | Proton pump inhibitors for the treatment of diseases characterized by inflammation and/or collagen accumulation | |
JP6051315B2 (en) | Use of pidothymod to treat psoriasis | |
WO2019226349A1 (en) | Oral composition of citrus pectin and papain to decrease plasma free igf-1 levels in individuals who need it and methods of preparation in soft capsule and syrup dosage forms | |
CN112439066A (en) | Pharmaceutical composition comprising chemical ablation agent and pH adjusting agent and use thereof | |
KR20210039413A (en) | Combination therapy for the treatment of cancer | |
US11058707B2 (en) | Methods for treating ischemic heart disease by targeting TRPV4 | |
CN110193078A (en) | One group of pharmaceutical composition and its carrier and dosage form for Cobratoxin intranasal administration | |
EP4375278A1 (en) | Immunoregulatory amide derivative with improved material properties | |
TW202304424A (en) | Combination comprising everolimus and amcenestrant | |
TW202304425A (en) | Combination comprising ribociclib and amcenestrant | |
WO2020205608A1 (en) | Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto | |
KR20230055994A (en) | Use of 4-hexylresorcinol for treating diabetes or diabetes complication | |
WO2023039168A1 (en) | Use of verteporfin to modulate wound healing after an ocular surgical procedure or ocular injury | |
KR20140096172A (en) | Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21887838 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21887838 Country of ref document: EP Kind code of ref document: A1 |